• KSAN
  • Contact us
  • E-Submission
ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS

Articles

Original Article

The Development of a Scale Assessing the Risk of Discontinuation of Tuberculosis Treatment

Korean Journal of Adult Nursing 2015;27(2):156-169.
Published online: April 30, 2015

1Masan National Hospital, Masan

2College of Nursing Institute of Health Sciences, Gyeongsang National University, Jinju, KoreaJFIFddDuckydqhttp://ns.adobe.com/xap/1.0/ Adobed     ! 1AQa"q 2#w8B36v7XRr$9bCt%u&Ws'(xy4T5fH  !1AQaq"2B Rbr#u67Ѳ3sTt5v8Sc$4ĂCÔ%UӅFV ?_Aנj- H>>,m*>fzp"TrKkr^r.|_&]|*vPuܶvoQ1mwVJUhu-I"=LniAƕ8"۲ k*ҿ[yu:.vUQ+)%F DHyVBk>Hy8jݹ q~9D4KRmzQ)^ʔ.J%k_tVi5NTjg!'ky|5asOȻ)R۸ߩFMԿ3L4j6dڜ#NIwUF]JqB/(FafJRzq3\G՛ ?~\ 6)6W4m[O^L0E&rRMض*C .]Unl-1 1r#Rj/&QɈ׉˩s6Rj=5Tg.y.·Pӡ:JJS:C8-2u]d&vUz;7p9 5VnL֢"y)">iי(IDDd| Yj0; LRfS:ktYK%*N2^m|&dğth":ey)uPQZW)gcC3Pv&MMWd&Ŵ۲mvTRoժM03*F3Yd6\8,\hݻ kߔi<k NTwSԪmljj[>->ptU%'LR>&EBH$MQAUx[$Z6vi&_a.KIQ{hyƒ j"JOC9eFҝfj;˚Ω<[3_m% lQ@4g=5$(J]Yc-OMq<Ǎ wSzڗ)k$7VIP붾ͯnV+卵*t]iЎD31~SA1éC2u)ʼnQn-Uoi3:grI8ؓWm*G zܕ)ZקJ}Y YlGeJ6cB2I NS3Q>k=KTBT]W6+SOXQgGR? telˊ%-Re\hѯ2TF"C/OJΩ6r[N.0{SpljjX1“jOsӥ;ҭhe}xu`Ք&.)yO̒ Fߑ.$Qw;9Iw2o+RVJMSOj[SoҌZ%;`d$blQ{Ro{Imڌ>3egf\O֝Uzx"䢸g+mv%Gʆ:|V[N'&ס-ޝ'kfE|K,G&˳98Juin/\\Qݿ̋v~Ǩ!rtWU d|E߫R4d}.qPw*Ӭv5YEcn~f5c%MTMkb-F>5JT,})QHg%{("ӔȸWMsYyWNRrkkJr0XドnͫT}r-jj,Ŕʍ\Q2Ri>v$5!]"JB2WɅ)]VԜUc8i|.jeRO6^V.¸ Q&#|ܶ-*uOG%JAtRZRr]FFG\۩w+?'zչSѧt jz>KW&ot{7P&2D;&\\>Q2JzܗAKSfeNn[jRrԕf6,q,F1tRfԗ>vֶևj-&R'Zi2=xv~Elbsvm8=ӛ"ū񕜈BȩlWau[]ٷBߨF~J!|Ipr3R̴#Yp)={7:G{+:\W}n|Q#%)7^-h"Ƒq:M*%J&$T軨I333׎g_- ucBwwjp[6i25$̏bU’ٱRv?G\~#Iͪb7<<}Ezt" q_Inw,7-d,G÷%T* Wg1"䥱kq/A.,_KhqŒxwvo u2ۥۧ.bQ}XκA$֣ +K״ZUNmڸII{.v{5z5ѮRme[moyƾd~cRݾK'j.\i&/S6f|b=5: p!6i_ 4j6=.si˧eƾtS^c.Y^RJVS-Vi3,esi08?H$GvZgg?gi䤟2adw릿:"۪lkSN>q-4kI܋ێe̊qۅgDoѨ9; #T.Q;7#~_Ufstb_'w~Xw1Xk,vcOt._}v}8"(4Z\ۘgk?J?bm_c!g{HZV]Fkk%~gEt)b秴vΰB|꽸}mp~E6ݹv;7P٤v+ri*3Ԣ|'O14_~7nP{7ZU\Vű[ +7󖱅o#:ǥŬ\|3r%TJX]V7ez¨Y]lc|O3V! R zbJ'PnGqVJ"19WVeOF埜EaEJωqCN5Z g-9[S<$sUK5b|7sn\7x qmv##FF\ w[=-43$^ooVSiXօv7iB۴yg>]Vf"r$J3""32!Zh[K%7GvNLs+4nB/B{vlsobJaҺJR:0g%&zR\ S3T[&ִor*ⷳc3ʊO[iozW٨%$gn:ܶWwFBԹjHP&z u&F2\f;ipW73 [; '_̽b;vib!oec dC-tS__$Xs]l9&z$2/N>%'[}b{h/{`{Ji׉׏ YJB/X%}.|+{(S:qz]4_Kѵo`^tY_4S#* ^zvݾMr+TrkQ g.8Ͽ^i>ӈǙvix>$o( ^qt*&t1oJVu-ql5U6jCЉmĻ*"?JT=K'O/|=Vo}l0b}}f?X[?/\JSBe,kP8ETJ==?.p5ފgbU9}ǶdNKk—_$8̸͓ۍ8Di\BԿ-1v{FF]|.^ۅ{vl12׏z7-R7wE?\nh\jN/Kձr_oBw"N QMBZqe-m:ӨSn6j4%!hQ;sv'm4kcM=!8\m[M4{SMliۇ%eֽR&N:{2A8)THLK3Zj[jPBx#BگMf:G1\`edcʮ?|w(-̮vXt,bW2;.ιNHRR#YwTM"<;mk\.foIDjmlJ;vxy7o7i\,KQŊ9d^Mmgc L*.T6tLeIuOH3SJQ3=F/ʿ<9\JM6mN6=<{xkP!F1QR[I$6ُimXu2An2yԒMU q f[IB-'䤯jYm52&JG\zд\~vdg QtHGXw&1Lw+nDEdC1w|YJmvP)HZ>i0BPβә?R:QO["]I_Jʏۍ>QKyu^bycBq4lXF~l [\*N>-J6,Gq(Zr5h]CwYӤU~ʶߑ u*SIv%ZfJ7)! FS*s_\|IŸZ)J ]ܜi4"z[+Z,MOZ))}|Ʀ(RUNIII.S'ˍO~˨rn}M)xxӕ0 eyҵ7YMAB]ӣU:/ѭ*6bcwP͵ "+qēVjŹO|GtY4V j[mLV M -m>",B$ GD1~j6O4|LxnNmqATNR3ε|DŽa[fmn-ڭ+FiK7Pcm;r5 l8r{#-]'nrFh2ruycb;pW=njRqRJ(d mnpckNnʹ+6]tz~E=ʕ l ZZ5jSi3#47.Lcfe`9؏v囜.F\-UZ:*0_<Νu9Lӵm&)_3\^ҹ3"1n1v_|uRʞͫr'iȧN_kH׺8xXrj=\МH)V\ˬ.Xʸ oVRC}ySU9/OBY먌5 ٿwޞ)rw8Ӫi5*5ZΗcGƱ !ZۄlmpjJ -l <R̵/JAպZuq\IdUS 48wXJJtcg4cI~aqߓwŷrm-v)G7yS^7H^-\mŌAq|"m9IBnF㏉9[N+mmy/!KKۉ%n +BdddfFF6FQRN-U5;Sv'm4kcM=Mn)\qιqUd9F%",6MGdT%-+~ f%+y֛^3SrF>6lc(֪vۊN;g._0Sѧ]ETWرkQKzGe9ʨsKA"yC y2\[5 rԭ7Gk5Mzw_4sM3hxЊ'oÍ5jsub )ͪ~tR2H]R͍>̋m6=%(˿(Wrr-܅y5(ܔJ޺YunW̹븹NsqK ]/QR#"ZMDfD|43Qw|._ԡSqTZBg??O Ϥ)/E_U|i}2 9Z?¹0:x'3,whǣ?C y-A~=daJј&M?D1_PS+Oi&;a @;Dž7[ zZC"bv:jjMQk$M RԸ3uA\=wI.AwC"^.{?-\NSiˏ"b}T/}q/ o.1M}R%:-ZniʒL$SgrBW*,Mw'N\ɇ{s\j]VryG'8f`}'N<*/`U숻z CwHq18J+vԕKss4R53/&XTt1bZƟo\=%nO)h$rBi-nKĪ^ ջڜlwkYm[̑+/QrZo%TQ;TLs($2C:s.%+eoNttq۰kK7O0m_t_pZ1SsSM7"mevFZ[w -FJ*T*jФQRg BSu|]g:ɵzjqwmltL.e3sRMچkSmjkmWœިm++¦'tILk*բQ D,PB\lI[9{%Gb R6öۍmX-MaʉA931cs..G4CujQտ[9 }G-xwl)IQz j Ó"rqe&=]꾧֎c)<kӳ+0JrRR3'TnXi^xMF Bު*tIL.[h"2"nKzZe'ZV/RrNYz]8죝n]Ķܩ>^Ժ]u-7^\mZjܣ9+Rmn ߑv?oꋘ?&ƪy^N4o=3-ؔ̿*`}V݁ ƒPu8%$ ݗ]wt;\y\>='OjPIp/nJU8{϶FNMsf"ίNqƹ(+ ݮF2Km |jܴZs%zf*eȫ?]4)I۵nR&FX + [jDh(#哑9q9Eծj8noǕZf\J-l&Z˫}`ӎhyrΉn\űn]9pʌӣ"׮Wt?N4_I_~54#/my1Xr*척aS#DT >q ssΛW;3oUaJSRMDgQnt:Ql,/ ܷfRqiM Ȼ>Cob;A>ڦWقM9X~/!'MW.}Vrߔꔵ!5|iB(0-zF=}okڢE$^wW~nokY߮\6՜̌{i-AF*9)\t9IV6۸5ZUF6R$ŨQIq砳YUZ]eyv >hI櫥N )&l JulwE1GDOuFN2| }馥uC1rޫV+^gdb&W[4<^e4YW,d|htͮsUM)۸8:{3d{AѢ)~ \#J=NdƮꮓ90 |1K$v*?мS ]i$J,C,SG?/_՜pMSƯM|mG1V1$~K>CSvkuj=&) -,yLjuFHK{c駗.SOua;BrSqj-ۍZ#'Jys7[g2z/.u4+XV2VQ.ޕ)$"(%)#Z7suZ%j }BǬݕe)Jvz8zJf:hIN|svO1O#IEcۍjݽ:SdὮvu^@:o^5cs>i/VqmVm]ؔܢn6'vޑ̗J4Wn@OlKbX ;n:hgJ9ŻyǑz8f܌q&Y fN0N;[69 rbׅC2/#kE l&2~èMR.*%g=Ft.%؝e8<.e=Uv{~㻏"EˑnvDѭ͜Lu3u0:U֝$[M5<:oi+V4V9 6nXvx&_ q Qqw3W:uϔ2yb/(ɳ|5zQiJ#r|Hw#.W?4aDŲ\ugWG;Cw鐢K|xg)##=O.dF˟jMUvWĻsr.z]kPc9"]R)mkfOd*uYf١RsB Aîh=k]ʳUrrZsq`d#r$/Ը3o^&lRWȍyuW̦Y4QDUMJ65ƒ[+ygk XK_±k#y:8(TJOSQhJt2.DR}"5[) r)6V6u5k:eXZmv𭤔!푊Q[qQ}ҹLE- 8qIZG|UM4j}Mܕ[Vwm{} Naqµ"ԈM zOpKѰ?IAD3Ir0'/q1itoB5{%wkOBn-ۜduqIzYK60{+DʕܞqIt";r1mG/\/ym[6JƫR \L=S=OT@Ix[TMm{>ݾտ֒ݸӉLYIx>+"JVNzx||5rI?C{oz8۹e\R-^\A2F R+N9 vlT]"ۭ d)t֞i #E2jB@׵=#/N+!ĕhx}I!cM`ąZ*ŻɄҒ߮Y.Z}='/oۙ3IpW̮hT7cTSuz9>B}΄&h!>lӵn~j˅IvU.'v'CSZw8QK3G> ,J59ٷ+HSg䧎hJdzvwv-cvxS5[̊n~ؿ%ַX?O0\6ne 6kn9.ϯ} *h 8_QhLݣ7q +=XBҲ5?[[)+F`=4 }B,sNg==u*Nj9k_GJ)+R~GSPBȒZ:(K]heL=vKPӢwq(NrG^ثϣ?#tC?.ͼ[ۅo؞y#%ǛjVyLSw%T*s92JTM%"YkQО.q)gCͲn8cgi6j1MѾ[{9h^vƘǚםidfi.^RHmg&rׇz:}݃}xT$ضk'5s-狶,\vpbPD،=Okf.c#cdz2FK5T!&)|ntD<+OŹU i-G[EE*FDfeaf2QƤM\UG_{ǹm%\yrGy:.\4wjPGUJޕUV7Do\7Vy_13w;[?c]H\$IJ,*L]3b%L{y.JRKG2sq,B6T}(#nW|km+q5] r㪍bJ@y{byz,b踊3ϻJ,'^xd،)JVw#.Vټc''ÝպWtbRؒJz۠8!o9IۄS95E9ؔ-e9JR{dmnッ<[~n${~Њ$W?&ՐY_? #a.ߑv?oꋘ?&ơ|y^N4o=3t=~7!/M3>n8W홎2M`Qx+ z qy8%]7_~540ۦ彷]Wq CѡwkďyF5Dum_}~P(5.(X,K9vᯐ?leB9;Jhm#3{CxGE-S{;@Fz˙]=O'!ɿ]' r`:7'2bЖ>Iy,/eTy/V<.H?UYY{\^#ѣr9^7?xoRȆ7EoS_&??zϾM?(~Q-K&>"~aߨ t7Emsϛ+?;fCr)fY+>z$tIkjn_>vnrֳki-˹l= t;'EyC¥|/BLwBJdgjۛ$s S1|ɍV%JI6KvəhzIlBYɒ|0"Sy0F>eo5W)O+X˻u';v)2vVq۳kۮws?UʑBǴYO漪e2MIjPAک\b1)DDؚKm6ZWΨgȕ۶yjڳ 2ضN[C[|r@9Jfo<_eI7q.|cÊV߷:i.:$ȋ)1%%)ADZCEBxJ0MJۥy(bNsKM9k43IwNt.\%N簤I'.j|ƃ2$grBEٌ\}9:v*!n7M(ɽ]7c@XxƱԨ37īf62cTTfFK]9wntQHͮvٱI/f|j=7}\_V5U^+:uljSȃY(XI.ȱmo1甅jڎIZ2>#\*:gY|4k\8ZwSqtyA!+];бޞKծË¥e)#5ap.QK^8VdU{*ѽL\=qmjnB5>{ Ӟ`v±5 ^k&O~Oshɷ,;6nOW>u6{RqS`)S%jp\ipdEBLfTWy$GIYw~䲭J.1vSY5z.V>^+Ǎvc.I[R{QsNR3ӎfhd>y?UJ*}~[e\i5U^͛E]G_FS(Iɿ]i8:4zj~շsW,ˆsy:%O}iur]iF5~3M:Ӟ#N06)4ߧgdawIotiz:1r5YDZLHBSi;NQc44la=Y kQIT*ըl:tq2(է9VO4뒳܂~2rq'nrVZŦ[t7\oլfb/mlpc.I8콚q^1iE~䰳mi[dۧw֤ICfdFeCsg:i| 6擣׋* 96lust^{%99UNRvaMܽo ammi$em4D6DD\nA%$$#}۷/ݕr99JMն[oT޲E"KTaP+HGkŴj5TM5xƱOS-k`ۛkٝWz;{kS}F;~q|~^_|euwnE'pSupUP)V]vE+t =ZRaVdG6= *.ϼnj9:UɷbېmF_tޫgHjVS'śǕًdkkѻ_]Kv?nT>)^e=Ar1'3ԔILyD?:-^in):{7.؂\.:V }#뺾.3r̸*xbFM aȵz 6SQ:ײj[ 8nn iFMw rR"5M5I旘35f^j='j:nNW.ʭocZvZKV^ɚJ.cM1ZI7E'6rg탸5oZ=[m Z`\hbMUR١Ȗĉ):Jin!_7Dй+f̷eKҷvͨBPR(V`y6tw*MRΝcB.ڭTnc;P$8nFvm4(D(R#R-L -2:FP lxZKQc6I("Km%$E, 78uXIFA$RQI$JbInG]c[ֹ:ZM+n^')JmJMJRu{e)7jQDw~%yQl}BZujSSf۩QZ+Dzhd5o%BIc'GZ?}΍:>Ɵivז-%݌J5MqGWTVʦh݇ܟ~Օ_6 n'{3~mϬj'J11OȻn߃r Qr\3y٘+WӍ'WxEs^O3 o~[|7>]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%-(\D4h{UK&ӡn^m]Fݢ:`δvj俜F+) y[{{ 7 tu>gvrěOj'5 iRg[ͶFjGe n~qT$ci ۚ0oԹc*jL[sVWqj\ݻ&6"WoK:cnWmrv)o>66(F>=W^bf#c zzʞtپy%mՉPël e}J.\Zk4ttt>oEM=q)hJjI=ͥ(%]脼_88ф;͛gWG;Cw~˘$4=uWdĜTثNDkiQL9U*O"4XP`02,Ge-k5$h>ܼ]3vr6!9RQPIVSnM(ۓ{>;/Qͱv{3&-[rc)ܚI$n{Sv3[j00)-D3z}MRzVQпj,T[uVs0\}Sid;r(ݝJ>æʺL&c[jPK0~d(FKÝW\m]GTcF|Iׁ)I3~#oX%vҦEݑؼ5Żv2qAZTE^..M{ʐfȏ2##.R}*KʛZz^ӞN*lPťLf\G6[WVQquV]XAi)5J!,$iJ6o$tPZc;Kjx_n3`qIelV~vLy{fn匋Ѿn%;zV.n'-ұdd2߽1bZksPe3TI9)$ԩIN9Vơ\=2885N\ p)/a柛w9g_lױo8ݷ iixJV& ғRi{N^_oAŮE6Y7I$Nk$|Q)-*4Z)^¸%4Qm [I%.c-OV+C֧R#%ѨCe3i;w$G+_dy| Fzj$DI(=OA gj%v/]8qԯNIS*֩',Q%\44ZZ%D|Ǧʴ6&vֵI$%8(ԬƾS&#Z. }6z?b/|Jl{ץv&mpx4Z$”ڝ4-H%dGKfM:sKSRWeJAn]>s6应-W9'H]'uȫYvgK^\czp|My\鏩w/ËQ.)]\QiS`8uL뚛̸=J"ܻi\å'-)54Ue]:K\퓡vK xwBqrH\*֕TnzC.mT=t-H]SČ~Nu╏NÅ3f|͡G~B+Xm[Q7U{9"~jgK Zoʰ7"qJ,ekSeNGgϳ] ^.6:s}_,%eRg<5⿨z{ZPun#jRІ.6g T.!]xa c#jN$Zpl̋H WZu8WmMRýsĮ?Mco~sx TU҆Q :KDG4n42.<3/'^?6/ܠڒ^yrrÿr2\D}}B]^E~^T cɛ7϶Y[<֞[7d}2%QPqOLEQR\CIsj1?\}%tJ0e~ *sk"*)&ۓEi#{1J8Hrt|'ܝRr8)=ƔN'RVz:cf]F7bZyZUȘ4x8,#JG̒?.W9XnO]KO]%]ƻ O5Γ/3qÓj؍/r̺rƵ 5\&m6h.xoeX[=<3%< lZ"2h\Z[&jW3ejm?k&[]ųj+{N{66leu_+lj]q* 7g*knأYv= q ەdxЬZ|%GUrQ3jLŒqET]1% qkXYūYc[7Ś]QY\jko\</Lc7+'hMSUc6qXyؙ~6#ѯv.0$BQi5YyIhɍiy=KD!n3Vm[V%W-B%swa97ajۗ m+9~]fKq|Ddaˑ0A]_v޺mM5* F-BYHJ5}q>ʉ.6hyDmpD׬'-_v5;5[8K[viJ.3dR:oYHHh9I7:۽fi+wm^ [)odPѱ52CZUJicSw\&_s0uBȍh32džzQflcd^m|7GѹE!fO5]]H9݇ZomT@]?5B:Z߂'`V_+/MSKX߆ޠk3?o7y:4R/7þ] iG߬aBRU&?r&/} cQߥGj2?C5Yśe7hU=?+ x龳f-܈czW^7p%5|Y:SJE\U-(a_cƣUǽXXKiȞNlmۊڭڄR!**ܤMeȽ$|X5(Ź\rJ~ܮ]>'HB0cp XFr_c?f?7<ukSgov¥iG>>䙗i.+t+bOjIܶ . i^:nm}s}(3>NZ$2Qg([".>i.ƾ)B̋M8+"- >eE6DݥJnJˣt׻ 5.˅nJGwZD~!i۶a,Db3ZQ3O#KO5/֍ozuK'GbRi᝘NV_ҝcvם ZoX}F6z 7e5_e:ۓj=AB+iܔERadMBq*ԯ DwI/Gy*mĥiRKg6skY/#SN4e$-yXM YL?^ĸNNӪ{$r1JJRSLO]Aqm>V/s[~i/j+m>z}eI"Qvp]{ZԼ:{vPAG2=T͡@ڐ#u"E*>C;o$~C#_d/HBq^YRٽzIKbOm\~żjFFGdiQ(*/i*#.FF]©m=BmpQQQSP&Ҫ!T&^>:y)$ˑÐFčI Bӡ-t!bM WҦŶ'UZ=}zvn~oT/\ǒ'nr8 AJIӆz<^uߖ4eFC1i+v!3qNyߕni?4JZlmYFXFۼO0B\m[ tʄU3s"Sr(NJ;SKW72L4̏BVdf^Ҹj\]ȱ۪(ӷm?J-KEmWڽ^4<8qu%9pŹW~877ܾeVгS(յe^C]yX͹! םm4FGȋ\y'Z FX7e)|Gjt߹#gb\ŧq_([R8[qU$Z (ʻezV2V!iQ,i$JE˂٩ a(GK'O{vnBvryRd-RK4=qxZJMl_CuuIz @Rt㮽޳!|68\-l[џ84-2Pu" RJ_^OL>G1~XnBŬw6J0*Uvlږ1N G1q9IUm*'oWu][&UyYZbBZRZNfEJf"+2nF~Eû7n1xv.RUM$6 lAxSQJ&n5ܞwlEói"#>4׿Q.nEq7Oko[1wg8ZQwZYiqtm&~">Bo?w͡ni2峋NCEy Ҕ+%ZJ ʩq*fpˤl,~^Mχk1+:ݕ z&Y`KLӪУDr3[*Z :(SL&ݻ۬Vqsyԭs x|iI߽zZrg.:mp%6ԜvgmpIUt;QbS.Է) ǨKSV,*lڌ|5Jt3#NP.=+OZ~/G سIgbꥹJnl_DUM\iM!֔wVZuԺ,yV.Q>f v:݇WiaŸN5Ҕ[M7SsrvǣrMW= \8ZW-jsnڕ.ZnF2qt ً[ٻޘY۷Zm"Jxr&NAfA-݌to9s359݆mZ+N1-qS$D=17 x׵+%_ ve4ir6Z$FDڗnFtOr'7'{9C˨ꤡaYoace{Refnft RR"4%ʌm:Sj3)OdInTO>X'vxV#jܮw9Fog;5.~Y5\~18YQܹvj4+~t7S ﬕs %^۵ڴDZV69R^Y+rj$ԇoJKR5wB9C>Y:l+EǎS{ʲ{T6Wi* ^^9k/y/Cs\g*qڵgn4T8mERr|Ti+iPe;;.i\EBEJ 丬i9ɧM-ԼsGDrZ>r#R>~X9y4b棇9JwV۔%m(b[Tjvl}۩~nDԺ{Zo-YuK1vx.nWuO+jN [ٮ0%"΢CdTJK-RަH"$I(*ve &҉FzB,_Vpqp9m8werv')E;o&QE׵^d9˦j\_,ڵugZȻ̧8k+jK{wmr@3ӭ2 wFkzFVqs1؛.v'I%$[iT]D5Dl2 nk7qUxԫLS+sا3/ΖeZYK<["%-g/kRs:f3;*E ت wJ%)5&+&rw*霣i|sMҴ|;R+fm䡩.!**dӶ-6s6,]zAXMWjmnz%SJߴm2UXw7MQ%<!tKys#P,W>s;3IYwx<+i_\\\U6 u7P|xbn_k&ӓVOe䦒 VUr,-㘘"-LZeOSҠթrEvq8Kf%5%&K"#%vD/.ZYYŏ+p$nZkvއuW9㓱Z G wYIFyf)?ƎUm5ԉ/'k84{KO:rQI}XRuԪ|*lu)3qZ[mSm5R3".Xcَ5c®ࢫI*۳~wRϿQWޝ(EJrri&ۥ^ʶ齲Im|[yb;mnm֩uiܘq>E+Ikx߄3r33-5𹻖09ϖ9[Tz~mr5NsWl$oPusޛ^{Z;);sڹf\3oٹZmԉ/'k84{NO:rQIBø8Bݱ3n֤DiK4u& ofSȒܩx<˘|N0Fչ]qsp"}! QWw@t4ӭ+cO5%]'*{eM߲DRO1y*q8w++e!c߶ܪlZWّM欼 CQ̼빶lX{vib/V/ ai;x6~]+z]MWB>re-:lgk}պ!#9?%܋V-c[z!W?c7YNm/jRr[HOzԻefճ0q15Zp#rkQQ0tU-AmڵP/cȕ?0cZYj;:0ZM=D6g ?'UN+ձ[K ܖB2'xq9{|۫N0ku 7xaj;n\ 2[VznMlWiKbSk))f..)Km)&bGZ=>OR܍W:j'rM'wYz&/鶧{Sʵb"vջq[I-ՌZH._x*BagC'T(Q:$ͳQcMCKy?3g'ߝqnT);qs #ؤZ}OOI:cfnc8W~qy.;^pVl]Hԓ>^H^@7-AA܃nmL(uWܻS߿ Td95Bdh4t6*dDh!EhI[iŨ\L.&Nc ܮf^;$R)\rip9I|ٺ?#R.ZDZ;/]nݻqs\QE9M&Bd ]N mN*D>tgbK>+ˏ.!23]BȔR1ɝ^j'k2ƮqBQq[$di]icV/e`޵B.FIIJqbi>Ӥ|p; 6${)RU>_e}^dzdfzi %ekRVUS?6'hׂ)5.\+qUgzE2C˷ecŏ^֔ibk shesFWJ#~> Wk~ݨ}ڶ>ơǚ)׽ZƉo~B-ڼrvoE:Ʃ3ۣK7+Y`WirS):{>ڛ}:wԨ(J_";6R%[u&ƫdZ_\'np| RJwNeTW,=rrbnkڄ[M3ܴz)3- R.?:okۼ0TU'w{6&w7j1z3ON'fGoO?)S_bQ_¿R(^ԴԴG.EtMڇ&RUiW uQjU> Kiu1d<ѥIQ'RQ1:O/lŗᏩiʂv&Jc{D5 Tt)1.n[n۶X}RjqnOʽ(~[Ns{ސ⛌uO,kgo֢dRNQȄ .'6W!׌P朼tdZjFGE"]K@'i۪N;sI[{SOzk>`rRR+!σj8&TjlvA̷Q?HyjyLHNտJMjܶT۽lG?SnKN%<‘ nq[N0Sq[Ta(&t(|HGO~gvkݻTR4&Z$#ViOY1r$6YF?e4U/Mvxų:zbU^gQQ+NW_'4jfz^c'#`rvrڡ(IJ/J ݦ6 ]-CW |_{v*_q3^DZ}Ic6Uڌ8p7{crZq5ki`)mU6|-Z5^iEz3P=:Cu7DF'k%}<C-޹ֲ̱#\,(f88%X-N(ck0VLR~} G"-8ӏ/ϰKq?(#nrVTmZ;zióM4 m |UT'C^_1X.gXM{%ʤd 4\ovN":"y-,T)fLQgۢr=/CƹǨJVr[a+!rT|%Y\ٱzsS>jͱ.oOc6f$q% ǒGo;n[];ߎjrk{~\VۓNIGn:iqxo |~t5)Rxעri{Vi&NUOl_ѮMfsޕkЄay.0P{7N((BaIP$ K"U6Gl ݙqJRu+qN$ m#*p<|{:>-Ev=86N*MM긭U*uѾ?/^o7;'u,h4݌xښRM:5.(/ \իU.{F^rmF-Jɷ.>Q"[4xT^OZ~mK}T0ݛ^SAo9u?lX(' qj%=X}"^e4wˠ|rܫ 6I\Ķ;Ӻw!'ڍWg{ i U_9Avhۣƾ+:vs/MK[ɭīe{`Zgb}r[i'GE2J7Nez579wRq+Un ]J.cJ4M:h箽Wxxm^ pc\wcN%'My $$| :$Fqɏ¾^қP9J6Wxvu}ݵP>Z'FFdg"-; [¢cmWkÎT8nG%ݣ7*\խCLRYZͤiD&J#'ehbSyXK|y*ӞpS̍R`[pTr/Eg)K+92{_ n3zwz'oŸۤ+sOj J:`T>Cf*lwd\fYOP"R E֢̔L4ɥ :;.b(B02rJ蠟9>V'9M%)IqnhP<%,r'P/vNSwr#w"ݨaqc(|{kd=^0jTMR2ULNz|.<|^PfY22##!,K~E BEJۜ&jRNsHަޛg\r,v؜.jK3)[EJ2ii{KEiHP^&]Gn8x=K}Wx/KI9-ϵwQ%spܾ[^R}S3$qvq8M[ ozKxcqmJ/ӿ{_}7&ݨ\f6ZSyQz& 7ۉ[8~UNn|nkiTB+4RI8'Nc%tn{!]Ȋo.nEmʱn𵵥J A+wy#+ikǒڂ;՛s85'KmE:Ђu""Iģ5p=БbTY-ͽڔ詻ngL2Q}$de# fs^o{DUUsfwӶ;s1T,ǤtޒQ\෼J=.tKU,7čJ5 N$y3kdSMQU~mO[03 $zAڟsF5^뜞"Կ QHmrR"ӳηer+ҔZ]hE-6Jmt'ޒ=O[sQj)6K}?e4v_KfZheޓ=BV[bY}lݒTTЬ{ȫvO_qpRApVŗ 6ju=*BR)g "O1yhb=tqJ gtm\b3RY+JQ^Ō֍\յ\>+uSi{=x ^w;uӘ#ĸzLn*$anok߷CBӷ}5Yqvdž<( "_OWit5:EZj2 B ρ1̊fi[n!HQF82q1牙nqnEpT(2RMoM4ϳOu ':֧_Xjsg jP^(ڙ{2%E͖j^}ZU[Q$'U) <܂%!s"m R'G5M0<+zM6qYm$ڕ$3ǧH]?o2N<8F1̻r_my[Rf59NjpzBnl7*{.QP 3N&^BLJPjAHCK2Q}$#~YMq8 k(MFMU)8MEqTy+Tʞ-ar5yܕOXw!e;q-Jqܶ䓊Y:LC UE{/t>r"lI9)3KJjϤA 6SEE$d߇3KG*En|P\ԭTn6I-ƍKTj<1H_zwGr19wF N8ݝ+a9ɫM6mhePi%mmD! """"""*1bRKrD"vnrM۫mmĽm]ӡiG~e"˩ lhRTMk^MX["Jݱk7_ޕ*DqĒ&flՒ}`W}~SմZ{ĕ~wm*/{{ѹ_-0ط#P]xlڱ~Tn5wi*lڪ (JxioϏbqKYR|!|KN53 OS222$jzww%i}>N)E+rۥ7c$Ofl/LNث\6H9: FY󡈾I)fB֔JI_ ֣^: 9mY{66㒢7Uj]:.-os[R&gMF3˸#໹kmjq^8W"PΦURjʄWa˧T!͋ lW48JB2ko+ /Nw QwQzQ ے%$ޓ7^YL|r7!v%Trܥ &|M8~ybrn[RV gSn{{*#2#ԽᢏӴHak" ӌcwҜw&RJ07ױ>Ļ =^ BɆ)v32.M1=#6%̠tҤnzqMwԣ~s*%-j|_m*.Yx9Sz=)qE4 3pk+,`=kNRڥ=B=nŔNAx)Q$ԩȧ4z3t#Z2lҮYn$S%y- JzGpu|LBV7ZW#;Wwipܷ%(6jFG5#{$D"uۭ~]֫SrD܃fҎӾ+Tu>-ZTQ& N|$沸ii>eRWݳu'[O̻j8JۻEѩ[]vni= ڒ,[_%kC7I3Nv$4ɎЈeٸoUu:[}Do5|zNq=Tre%ɧ6&~DȍF]ƞG5q m]/w/ \ʲr8=oʔe9U(W"|S]uZd#?Se[W"ֿh][-7Nu:T=)R}.;ml*5Dlf $fF(̏T hiIUU4Szɕ t(%_|2 ~6eM;TƗK[f&]LK^CE2[ȏBOd;Mi|cx,^6;sیGpQ\NuJIFTJ~đArh* B"$H쉩eXPRj?sl"ԥ)su]xpԴY%VESH"ЋJǰ K&5^Ukzׄ8kEgS2h&Se\ Yl]WҶp-ZUvi7QS:4byqOo+[̺腋[6-_Fo.6[7$p&^ _GZԸߍkc.qqoI[9m߸YxOZЦ1uoiSH)P9Uʄjcq= S>֙NeR><;+ڌk%_qT].srNO?s[=vH[]RZHRMtᩗVؾ:/~u)ԍdg%=edVrISb{6vSu=(ܥ)mTv/J}̇8 S3ad:^hBSf؉OɔLhI_1d8,L><_A0y3rXq"'(۱;mFNII.v5_(^q~X>y{3צ I*Vܛv/jW' T'NR'j%ꔩ:mJ3SB}΋!-H-RJBТQoedi9tjENenPpke.%4]#{:>mkEɱdYWl\\\'nRM4&U>?Ќˉk÷!𴪛]]5}UqG~ݏI"O~s6(Ļ)qO~h}uԕd}Q~G,oE!&G&/]_H-O=o{k\̭bkv.Ô܈+;arZx)m?M\3lU$mk-CFXjTv6u' g:Vn_*qk:VC A%'4JV%EY)#BғO4<e׿jQQ]yUr4=wm[K1r׵%Iũ-O}|kC;/VcݩWZ)EHdžTru]8hgĵ-;=>U_ InvTm_jBM+QiF"9*{DI/iuo(=TzϖmPQl_v4z>T*ȴ>YF;ε\t]EH4ꌇ[VrLzef 2T^V>g2~kg5~Nק;{~Z~W}&ŒBӿS2$J?~(Yœ"˲ߩ\O]: J׉ښT{mmIѩn3˧)4LdFZ/zUG>U> n 5& ϴ-KJi2o]uKljvK3$bԔҚV旧iY5.ίfi96v7!v))FJM4{jG~Jt/lUE%pTAFe4qQk\ve۽/u/Im+W')v{\-E|Pms7߮DZRr۞/mu*1ՙaB܆ -xg3#6ۥtRogʌU)׎]ZҞNnŞr}F1Nnޞ;cZ{N}ۿMiuxʉ*3qi'9KHQ$WJxXyرŔe~[v5~/jN9Q4o6rJv FrdxM*iRjMzUinHdн7ᾞS=S'7 } ̽zt7K|_g J=Lq+/Bw_\ۧx\HJUPzQ<hqF[V0x==CsU7q|^ {)Iq38$_A(VgcKu06Ƅ"%i~_ˉk QCܣB8Ku/񋇵u([w}$F|8TՠI.E !;RJ^}MɒD_q2];Ɖ{5}*n7nEInO{Mwv}&q+v [V}Ĝ@%>#dXQ$f;iep.GquixVt x6bj͵mlKقQ[T]zs/&yەnM'W}!Fp_d^Tu N{ɻ'l{խ2.sTu{W^H&;1s)Pӛ6>$mě;Łnj= fLT)>׸+qReɴ[UR\L*P/!$Ӊ3Q 'K=m~6XqW3^W+ųO_[F$rR*u"T%@O +%# ]˽!aܽz{ͷvQh쩎]hGތ5ɇ*DzJDRNLi 4:{~2FmXY-zzĽ^f=]uū{/+&c:Ma{ĝDp2m܍kHș/(--m_vݮK(V{R}.k&yƴ7i^4@3f sK3^Ř˸B=]?gt5KbZB<e;kQLpxuWC}n 5ҴepB##~q= `x]KWF {GfŲ}?G.I9pjWkU]>={7q{kO/^I3==f1ɏ%nnʫ/Zu_yXN<57ۍ'vy/"8넭M2eԷ&Y,в33%IkjMr7xf nmQkX4踼>a-GcIeތw&U=-:qnW)z¥j :WqSZvԒ#j"KrIU)%qrmRoDGQ~SYRsu*V)  ,/x)MFD6O#]z 96[Ui(JRfw'y$GeUީkdMF-ݻ98F2d[o{Rn0n-xsV6Dh|Eb2E:KCOӪv4SJCr"J!!m,hRLD| ZYFm/X~ΧfrN&4Ƒ=Z9Mh.Mܵw/BdrܥniŪ8ɧ|y%œ[M=_tj?F!z5\evM:\ ~F-sg钬OWq“iiȍ<Gi%%n2rqͻllƑ)okw7}\Uk-:&fj솘XerV9yZuʼşdFC=rmo%~ZN78X(N)_7.Εn1MpJ}62jjJdI";R5&iLԸc:jmqiQj$ujp\{;v5B񥍪Xn Ą4qOERjzN(Ga٠䌡)p*v(J7#ZۻZ8O W uONb+^Qipv9GvֽƼϯrYƖKGJQDNPhRJjᡧC"21"9ѓS1;R_O7/WGz)8fE%F2ukmvSov/iZ&/]~KmI[:^~ͤ\kMi稜\ywJt3W7 8Ʒ~ݥeFgѼw"8VVSج\뻆}ݭ/J6Q)d|)zU3>k\L=;ow֯gN3pKѫ|wmkZ$z^2R:E)f>ς нd|#׆?\ǔpV{;\$ƵE%-ͪm0S6[n< kE[}mvE4DDZ^$OZ0*$~XUv҅B@^?]so#%ojw;Y#SxxueBگy v^i-)s)zV jC{7Gt.w3v,ygg8s]aE_,*E tY5k٨h=o"m泏:\6w噓aiL׎n^c\75AGkЯ0Lf46َ`egZ˓p/k;̛]kq!ݸzpԭG"}R9Ve>ˏHUjJ-&7nrnwG*Xv\˱/vN}O)ʼn&CV͍f̵]r\PMB-6Du-#RͰtRN^)mT _}nSȕC*_xBuTkJW[`ɩ`ejvsngP ڻ.-WUtܑqԹQj)t;vN&RNũT+8%IXӃ5fK՛-d9 ]CƑm|nZ-6=Hz,*aEm W3VzRšdY~Xf׀Xx"]s;)5u*ُHB BRGS6bݶؿ 9j[1*jױga7oX CUI%0v#~\-O-Ꙛuɷ쏪&5mY٦M`LJ2qK~HZbr =N'YobI. (^ ׾{_ ?OJ`S`3BN[}5w6:ǵ/iSlt=4F*d&T4y/#. ɵim5Uֲf 眕6Y7 fơ=3dϕq뚩$qTM-%r!$@A? ޾V0c~{[{;򥧅a~ڵ»&ڄv1ek=wb MLkNAԬw-x>~/r=e73VeVN)K%Sښe"+3uXuچrn ֺVzscJ峻m}vb㶓n\YbIUBT%*,0nov=;z꣓S/nSXSpl##k9mXGrZv^Gde!ŷRԠzQyjC]`gToPov{j~KRBMY}i[߶9KL2ԉO0K#m>wB[ٍ+n[[b٦DX ݲpo] [\m5qdT()mo4Oy9Ie b][wղmM~vmi۱~t \}$яimRk(L c Cvk7r9_r1 ;zv|F@KyZ[&jEji/"6$69ml#e]9s\{ScL}Ȣؿ0q/nZ*t,CLoD߉Njǚy=Pgmu6^]l-["çUʖMlʍp-"qmU>۷uFOJ%Ǔkx 'g=睋k[3u,{³WɘݪF]ՍeFX"Oy\,cچ=w/gn Ļ]#2? vqy-gXnR.^}ݺFs{ŝG]}e|#0mjx"ƬWكm?rgU^xVB":Dt>@LRbun~ݭ,w+v⪕;\U(RYa61>#Jm˞Μ9g9XKaG='u8gf}'qy#ɉw J]We.ʲ-<+&q%s?2dњztҼn`cΤmmqMdz O[-ߩӲ&;[tmܝVnr">{x<8U+p:Ig]zjGkt,uzf}dؠoJaکqEq -(:d<պ=eKy[˗^%ZXkX[C2߱\ITTLGzANM￵i]K>UsOGDDD.ZF6* ҃V Zhz{'xp^`wo8r0h ZmJ5"jb[l=yUu7-;7IT%:jFjߖm0tzU'K)څNۧYJ)4IQ}^KWm7kSP>q;ނ#)'n7&׊r?óM{IwR\j2Qn[v pe#/tAF\ϵ225q֒om6z})6҅*oqDsMf CNIN=T S2t,_ѧ}kveMF0J\Rnnݙܹy[rUc-j{yGtkQ%s]5qB.Nw.JN1LvR Ui5J ZESQԙr):MJ+g}χ!2;q([jAud][ljVK3$ײSJI=/|&tl'*n۽f.frܥ jQO8>&Z];.|7T/C}$ڋUmP2Reҭ8hFF\L 3~e v\۫]ݝNmrnB%*]Z«hKc=BTLG :V74$=Ǘy+EX'4tn(I:Ѝ;Df8c,k1%dJ6.j6ź{N~l6&*fœI7 WAlGOu-ҢH,,(ǔe뿋쩨kM܍ZſgRvQ' 9)?n|er˭|I|-fGK.rΛp8XV1%K6mvG+tc+qE&ǸC_Nm:l=_/m5^[dߌڇ.c<%:)tQ$Ow~-aY;UJ>=F)2[nk؆?훐M=l6[4(O.]2#-H^n#->&mp5~Fӛ+|| S,xag%qkEUzUgæBhߕP(7]kFnq?֖CpruZ6*rEڊtS|*tI*E}7R<,nUU֫^I7Q*mSly%rdȓd8hE<9oHhMfNSRj[i7D[Rj݊+kდq{"$$H?p\̅S?㭻;t~R߁)^/>Qj`yt[w ԛ;²~+ߔ_ YW~|o]?x^ᯛ `ʼn;g)T@vWn]>&4lp+$D̢1l|ȨF%-}.9[}w~ ԠLM9hСablfe&QoW!s?wjLK?s7yO>(=C~_nyǜu?v3vyo oI@qV-jeES^[9WoSܝh"l2C1a͔CiJ@3:Pճw=/7ovuk+\V;lDgն<[A+rX~d;m!_s8ݖ׷;;.0llUC+?i#_crʙ1~C.\–q ul8Hܶ2m`ܻM3Tov|Bs rɵ"oLS- DКw=Tv@f'6|YlD͓Y%׵-#Ѯo%:&!3o%\J<02;K87>^vgƓ# ;ݝmz^Y6=PS39U%~ &f# }o!muH;ʲŇ˷yvP+&.7e[3'vR4Yj̗IZ`e˽3o[WU{ m[sUbۋZǾۆl6~9'V*.\S2<Sd*zY[aŶ`]C$n.v^Ʌ dng>ەZ,Mmϑ :n6nϦezWqUJ4! ۇ4R! =>>Fn|Q[{pRO17ƕ~._I''00k=b՛o}Osðc2'o\3}ݭQ^2 . R1yKȣtAݿ-uܾw!`?1Whn|gzUo[ECWwjUIן)^h#1ɭ!/Z np;o;ΗŻkXs."6E`Z1 עӐ9Kl8qd q} 2Stt;#j>;խabONŗ=fwP1j)l6J̶|gV2`y/0E˛6+ԫ1? 6}KW c\KoKͨ2ۅFw–s*TԞLיuDx .kCzWXhy۶gLu|%TnupǺl-S* PRaLnT+c+*xl.v!.U=|; !_L̎뱚U=4hm:ٯ"y)$:>%(n}X'p[ȴ ^˒4kƓmzDx \ 'NqamP7nyN݅=j7%McSڵj%STy qXymvCg{w/w=wSW5r̹u erծˊsOm=DhEҚRb#n)QOxtվQwe]I}wCa'"[ۂ-z}2UuKP$㜉ԧ:mc<Ý>RoL?wu|%ҷ&K y_!y9 ??:tq3(UU-lkS'ɸ@jdzQˬR] EVPW1DJq2n:,c|ǻ̑;y{X,ۂ.u.b˕u.tKBjQ"[S園S`ٮdNبeJ&9Ơ ~0a(Vm٘L+Jr*vڑE( x0+tp˕ n';wm-ޜMOxX>{#2%jgb2M[`K*\5@8l'e=0u+w ֘鳾{y܀:R*Ya]"Ӧ%ktynlۣ65,3gU}{GYrb;ge'TKwǘ.,rpܚV]Tr,!dp /ԺU,xՉ>s׽~W5oTh yx?xrrx?)?ilbT׬,z$Ԏ.UH٠\U1pU:]JwSrGZq8àd驐,N67QYBӢD㏙W!Q25ϸo9ms-7-%3CihO.J鯽-;MZM8ku-7k9S$8]q2E(}bۏI[DKOK}3KUB^u %Y,u.-&f#]'܆o$x`Yu,dzwM;#oKxn;\[d7}Rb+*Y䛂ZuBӱl{j0O̓}LhK;[aֶaGL{Cb#S.T[>߃F]NK"u^LUʐ_ykW?!GRj29͖qa'0[npcDvV)qz9R)PۨM^aJx W] r>];eN3vxdmĘ(5W2K1䪖weF{mE/QP6\u54x5[hۮ-Nk”i[lUgL]J}5 S:EhiUrgHl!ŒJ$pe=q^b͵Q' ?6|R\,JA ڵ"TDꈭ:ymg`B5t%M] <N_zv2_Ortٵ/i/ReӮ*7[qүqEG* m"[I:6e^p"I$jԴęh!m)]GZkcjS!{e^z}+Cѥ9;R|/ֱeiUԏCNu2Zhcٗg$ݭwvr P8*7/Lk~I'Km1+MW%Bk|oOm>-#qj*|Dbѱkn|n{v#jĮqNpMIUm(7Liz;{ҜݞڝVƚVϬ+sO!OstGvxӉ']uӎ4g_ 1^-8ۦ k!)Ύ5O;YSB#2Zzχ;<.ֵOtge~.(RC#wFZeGZٸ6FFJ4e2ˇpJT$[wgV)q6muDGJ56q\I!̗ y/I~RtJ9kJ]Iy*'FN0s.[l!fw'y(7$œ WƫgyΙdMEU JQJv̋vmrۖ.jWR_M֨djYgSj0^\y'EoECjm$ IƩK>Z28J2TiJ2N#}.s cArl嫶nB.FIJ.)۔\ZiM>/hLĸ=C1s[?YMqp|94- 鮝𦔽/k^#NT(Y LS$6˩}{;5 )B۷W$qpN)qqoot}ZDVә;7TiK|6f3h$dԄ}fqݡ>Nb򗉉+ͶO]>ߡ_VtYf79ڰիF sq~prս|QM)g%l0ocJȨHz V;Bb/kLAcfPJ,ԭ{ƍgpjNR6VSI*$!yV足jᇑ.](EܣqM\qJ2eZT).<9UB/(B0j)mtKEj#׿fDI-=rZړj|'Nڤ]k*i$5qt"ݙPM6E4ke^Z8ۏhz$Q(R Ay2zfRñnpnkbkI:=j &ΝșW?׵d{+ύM'??XqeeĽ.[o=UxFS=ӷdZwenՄ]_X=ĭVa* pKs0ބۍfJ3 gz̚i|wnxtjc¼5${(1fXQ65ȼb̶Zkn>%FQMJXӡ{TZEVNᖣimT/37cNJUPnP҂ZOE~"-Rc4^b- FEͧtf5[)S!OZIښݲ͑;tvܡ+N)AR=hCNn;wL16-:特7M$=Tҕ-.R[HٷnXk sn[ҞD-0WS9p9:-Ϸ-jѬNu{ҹfv)[Ľvwfg(ٷfe+0mYj8Q1\ݧg]Eǎvڿc!4#j5̋C2"}BRriFp7=ô\TZ:\BLfj#I22װ<;صZl j 6:l"6]۸ K'6RTѯ^ئOԓV\?$x7s#r:Oh{ց=MmuHԷd{pN /܅:UE#Yy+(SgQ(Щ)RHzw>^Ѿݻ>mK&^ '$Jۻ&w%F|xfz%˳ L~3N?Cy9 v w/{ƿ kz3x> sXv}vP"@WyC z`'톽Dw%-tt yVY\wmuPYQA0iG-2JP,6/gˢ]u.-n!Zw.N7Q]Df}Q0({a\@=i_X7gFǘ8^⻲}G MZ1)WEfO12G+=-B@z\`||w6ċj߬m}UwRox֢I &c~XGP6Qndpvܻul'V7^FJt^{b^B(L~sѣ6@߿^xqU!ڙ5|Vpvef-uӥ^3  FSDɯKD%0r}FF穛r7 +o"V8tv̖NQU!5uFd"bCr^bJ=֤fM#ʳԷP0O-9xRBm\=`r-:;~3Tl(nXtXi%2Vٛ#vwqƴ`L@"H‹qW.j,JM5B[)WܺUeZFqc'V˷1W7V̾-MHФwn8N;HPSdݷC7&2j.W\τGŎ'Vb]c.x+Rx1%C2T{myg[qU|+m:M:շ8҉yWd)ՋWS%%:iqlʹmGwݹ WnNŤѩ5(9hTٵDdGUi-)vSs2 2{OnT$Xck n:¶(lASLeȔBjμPpTb2~N2~%^k[ܗ[Jzs0ӓHBKq[}JَA-$dFQgjxxFv4r/x*Rm% `4J(&iv7SkԲmSH1YWmx 8n.k']:Z˭_W >ڃXЩ. jTq%Aā[E}amc]D:rmHRiu:uӚӢ\p(5-q%e)(۬ҖȽIf<߽pr&ݫVfY91q2ĭEQgYbTGQ&,yL+N$[q*RVۉQ=FuTܻ>f>f㋳8N6$܌n)9&»iˤsX,݅܍ȩv+sRTpO}d?Wn/Inpȸ%O]StQO|v5\}7Zwb.AIVK^:wb{[uݯcytO߶S<{8KSRׁH̏N7ۚ[xkwYy_'ZӵF+>쌛ZUĦreE9F[24De{}@:ExWs-\ǻ7K-\JNvEk%:s˙#κ].oͳ;լ7wB6nwu:$L; DkI#Wz.:Xp(˅v$Sq,wn\qIN-e<5Oe+vuYTpcojUI_ާP8 O 7&VL8z$_B-H-[uh]T{|8=qVRN-:Ij:7PUtXϷmy鉿:RIM~33ӸS2#׳GdŲ5+/Bx{(WzȨ5Y㞎#|˖+ ط.|e<o/rߔX>7s}VE.OVti׽ .5nNJO"95{#q}Ay9do]R"M6z\tnNS-D!@3N_jicWsy*5uٮRcWv/.,j}=S)j5C^> Ie =gu9ӛqjtz]۪TMoߧI!Ǧ¶m:,"[L!{qAv-o 3{"KʼnrIkfٶj2ƙ؄S`7` k6jzޞ?e5G&6uʷ2%ԒRKE*G\Npom F/V |C0.q_eenƣ<5Oh'67ɪn[SĽ{ڔjǘzs;~׌(ۂ`ܢ1ƣ` _l9Va6%UQWh~P~\F^ZHR@:ۧCJ{ôGeBh;~ۧnU J\O+n2 RҠ)ng}Kh{5+S×ܛ.1ZjG)iRȤIN 4%{oΜ/eO[Nffd ĹK?nnԼMqX'܌nZvq<ķbFnͪaQ`5 s,M_լ?-@_{w{ӺձJ}GF[%v\5[ŒGkOw/ΜM9rjË%2+rd~+󲕛C9U۳r[aJǭm|˒LAʨSCq[XMۺoubfp:t+ΤĻo ][ zt-*67kvS7D·MMCQXm;)܎n_h%]4ܙnRk!]ڵsDUF"`R, &#R_*[z*ZqFXɻ]7|۵w+'pFDەs=r./ᐚm3Hשy yD"jHCr':sA65نѮ^o1V/ f;nFr3VM)e*- s D'H݅fӧ\*޷[k<7u<-]֍Q8R h|p=WlW3s%Q %3l}@U-K6f-NϿu|ڴmWN׮[׸F*mW\%r! C78:޳vBG7ŵ.JթԚ2x)ST!řn~9 W:Wpܢ件{xf8ٳwKE ҰWxVB\qBZ 2wMb[lGSnyԚ~z9ZmያvoN2Afnݽjf>)j3 !;gOYʹK" Wftڎ+׭b*2ϻK>ۢӱeyԪXISUm[z+ugX%0lϏnvg!;t{BqPj>PyvR7Cj]O%+ݲ :qiMj6W}3vC/R=4Som]ŗ=ю, TF6U_-\6MyskwMr&Q\wjKܩyMϣUj0*}RZܷSdY3>Zjqj6TgzpA/M`/Cmл,޻feE[/+uk^Vs1W$G(JsW2ٰu*߻q*Y޵.Wi:ur5T),=0uRmho.twܖiYwrWHntvEj8qhf`Ͻpf(R&>Ki%I7$QӖm-2 ~yߗQ-앑/ x[k8nw.c㩵k}]FkbJl:{.(˩n0Hqvαp7 귎.Gupx[N`Yq'+ruU7[ү+>!xrȫoSo]OC# d^Q]\>!ƛGw^Mx"-+%vdX-:M2UR%d>%l ioSu6lsj7D P>XxHz Ukà(n^Q V>5cVtWj SEiJdznyej[lE' 3kuٌNn4JW)gB {4 j6&]' m-(ZMEz8cz>WZ6#7+[,MR-Z!4ܓtCyE|umj1ƽvƷV\;%>Q :#Le(iVz5 4ũۤUWxX ^(ҔsլB2w-V ^R+; ˂M\z+Uwr+RWY⺧~ Q*JcYSNSλUd8in=v K낫k\IRרSUaCFmϿ5̗P|u ZTԕ}>oYѲ1sfP+sQkX8Gb~6r,s>^\,mGL+7[n-E\.Fqḕcl*Jmjb5 ,m]c}NXfeVlǸJ5eˡ$4%g~N p4Y*WwW٧<8v#;qԩTut,m"#Y D\5V`\\Lȋ];LȇiS6ϝZ l>LruR\v=ǘϔDg=ԈdFZ+M{=|,[;0>RiSi4,S5}yxw&(E7&fݙ4UՕ! ~'Id)]ǽu2K-fޭ \08Vڅ쓬=Vy^^ IhyKR-B#Ըr=]mܻӾ'*Umkoy rTqT_i,/8Q^<ݤ|4ԻO(܄"'5N~#m.(Ҿ2i6Uev&I*<}҄$eNtÛzyWJubW^iBW.܅Wڮg]irO6Ve90sgv.+sV޿aޔ[p?3q*FutUo*eL\KM'EG*ZcAFfG5J 5jj=MJ3OK:k˝'NMB7m3uFҕ\-Ywg%PRqMIyZGY9|μvn߻5cWݷa^+X֥vnݘ\v7m>Fgzv"-;Ew֝}1|RjN𿊀7g#֟*GQQ|#/bo]p$>_Un9гUbn9׃ErQBU-^vDmVh'<R[fdHT]*~}3j;nvjc7s-rӳ Y8[n[1pJx kX[Jk9Mn!_Nю6x:iZ˦U |߉^Ԛ݃hYxk &U^bwKk.[jE+P(˞=9j@snCv7%c_7=xǁ<l {t'酚+1F‹l׭:ݻILruǶkL-L(K0L1&>wXB(pm;1fpnlp֓%Skidkt(U +xulo'/ڕeN r=^pZZ:Pnj8Hf"48ijY[ N[yZٻ+=  ø:3 ?^ܷ^Sr#YK[UF?CuhC b]GM')mڏsNrܗI]ljq6VB. W,UK"YX5{c >Iqā> T:n!,5l2VzCl|+I[*SrjnS6٨y+x,@>П.g+!rn9>N|W>OZT_ut Y""v7|sfި;Pclm EùN,{'fNT%U&LfH8~1v>Il}统u6P˗c(WV~H^bMU.o*oOF0N:_:6Smr_.b+|ݶYY غF,mwjv>f*>QM뭱Sd:`N{l/⎱;n-z~"Gze퇎J5S KG9!Gn;N1 ݎ h6m|S?ɂ5'WOÞ 7|7^ao @mxGmi^jϽ>01Mf0լD3-2T. VXR"ɥV Kl J O7|u?bvа;6.eߓ|[1bmRr,eRz`z 6܎-ͨku͹Fː dPhYgZUj}nvX;z=gVեTv_J }\1n7w2J?ޘγc\E 1Aޑzq;\r]]\Y&[nsNei\uURje*Qk2CSl*xJz-xٶlm+|UjUؓ`Ladqiĩ!Gd\W~fz;Tn*PdRM&T4`չSWq5k훶(N"Ӎ% V]֦wb.nUO!u*J&Oӕ2e|Z=eV쫚΅g#+/RW:طnbi*Wyo)p{:ETKؚR(RY+r웓r(IF) VmȵNB:h Q1ғ|u8E]{,'$-TR[j49l*3"I鯴zhd>Q+\BkNF=.$ZR4Nwհ(IpNi.(Gi33#33e$FXK*NdWrud[r{xnk$v2ıh+J1TQ[#JQl[tRO]LHKٮ NӍnF񨔤֞Em'MILB"ԋ%dBŋ+p̿_17jzT~4pc Vo\ƹb9Rq-'1j;8ܗ)hE%DZKS<璸Bu*%*Yw5ڻ9ۣ^z4U; Ñk\U(o~G?VUĎ:?P?_F_Kߤ~ᓾI |pr.Ok\SklRhҪz{­P .}SktZ7UQ4ڌIM8̈eaӊJZ%FFZu,KZvln廐SNFIVtuNi?CM5]+Ph,{jN JSR$IS^tSUVrORYu.9WyP6 [Kiu m!X|]Y79ӄ)\ģ)pbڳr%*&ꑶ_-H*dzk)1 V3')UAϹٶWRxe'պn۫h7AR9 EAJeGLms!%D| A 5]/Q3eb̄vnVn%za\m kZnv([emqrIҕij|""><hjJשvvǕ|Pޟs}V~2&Z?+2N&Z4w@)4iSڪ_>/JN9Hiۏuf8'It[ȲR.hZ$ȋ_Y ~U<UUO*6b)Ovzڜj\R̋.$FsQuҊj^נ䈈y<zZIuP[}Qm=C?zN(Exqu/kn S-FzKZzOסӽjJ\)F3b!r5ٝ|;6 o=-3*λ]αb\abqRi-w޵⦪~b8Kpo)Z=>)ғ"5/GTZLE-輵f7ݘ۹~+&+w/7GFI:l33fg.N~۲\2|*cnermnnM+Fq"ѪIz%j =YW8@~gc/~?N'?)«qȸs➟n=k" X“m֮VreMh2[uݖ] *FܖN)MȐ`f0 g,C9̑o;ddudJ=In13:ݒvvdMUEJLp^,6t-@͐9'{7m{-3,>hnF;ѰM)->>+Ěz!R* :`e--m7nB\u{b U>[8֪]6^ߤLʦ\DFNo$$dͶlgno8OrsQ\l̯hRo8tuNo+ CTxu!2[>ctFpeޓƻֶR"3QrQuOѳgwQr;S~)6HhZw/GgVTmUf_yt7%$];zLWF̰xy2Ʉu!MCmš_0[W6jf#a-KLi+3Q7c^qg%s<1aYIQeZf+}>;S6L0]Yu_h9߻<ƅpmiM$AVvŚ,*#t2.8Y)-Zhshü97/#Oro"u^/uFgWɺ,p:6a,^x%$Yve^3PƗMnTP&yS}OJ '덫MH^:rXԴJۋ/rI;S*,+yz1hv)Qw^ڍJ2oL׊q(\fDj:^T%vOadɂnS}ZO)N*λdaȜkG_PIEO}нa(^iQX᯦-7^)%g'SJx(.S9zVɴZ{E ))ۅi/s7 VIV-|sj0*UBTHIqRf>FP$KqN0 R̻8j\GcC}IUz\i 6F)Q{Gҧ3qSzKj-Az VЛS-zy:8*mNk|D鿓ND2u+0Yŝ7kqm·?8Ib]u>˗^_>(]vӋzv+ݩ){vZrJ2RQ몋C$z [,pp,8mڊbR]Il .f~d/ݓs㓓mͶ{mgjQwn=Oic9ܚm4Q/6ݨ[TƧ?nԶoytf{@AzT{e{[O'ZRZt~AGD?s3􌿂ՉIw'|~U\ w~di:Kޱ)U/sU%njѩ&GSP^ǝd)..!^U` 1wX[aԇSxoFV6_扐)T 2Mfd=ۖͭiZ7KK Bi9%7@<3<ճԻU,},a}FRqɛr i@ONJvK KLN M, ʖv0n-]DwlI-X6ܶ$Jʴh5O+mOI+Ra瞠\ MG7BفjYo1#͖0V`Ѱ2M?c8>-Crt*JkIGS:e#hPKx[鱼>{5m;wcն&>j-M֥^َ) 6yȜl_w{-ō̱r> U=]iw3)r*]:K]6BdCTZ|>gf}LW}[$'Y5 &c -j.z6R 67MԷFMnÌwI7w5E}o޽+K ֵy4܌ȥW"COyR[q5Ӱ͙f[v"_#q{MV6܍3"u9BK(41ӯqˇc${ߝCi6I(OmθzҜ5k^:>Jzw.>qV8{vU[ڶEm|DžBz].KHjI]x;Mɗ{m,qZXr忇2u^RO2Z}ZێS[2Jen!*NDcrBUً4<ǼMҲs1Zw57c3&ĖڻzmP*FuJG1-dN:|OU}ҵgi2t~F^^Z.VxjvŧnNNh<:]^~NN+ge^g.SԔGFe߯'[vn'(ScJ]kܗ7eJOlRrfziݮq̋S"\*U<*W]k$FջV}? 7g#֟*GQQ|#/bo]p$>_Un9;l S VvQU%OLU{οmU6bZ1MTx%!֙Q7, J=!3 ;Q,ڌ;6ͱ݅q^&ߔ·n #WbwӖX.HtG)N&d̵zpI,n cu ޖUj+VXUp[w]N o.J6Z8Ts&utxln;~HPHS/xw`G\ʡ¿rj Z^vt"[L:SD\h0sUwR,}[x^X,R2Vn< ]2YDr[SRKs8tXb̷G?Ps Tv 3be,zVz D[/I.KOEQrm'$7|[J>r S`5յwT#\w1FTz\Ԛ &"ׅhSHrD\'r]~/>p;:Piuu:"9ő=tTaS7V2rӷk7mb[^WmPp*[y.Þ6f]cizJCgRR@UVl큝.WJP1N{/\whZ ػϧӱE7|E֫Sί.x-Y&pi%v''-x6r'Ws*6=DwwUu]=C?MK [yrtܒG$!WGqJ*%SAz ED[^)/tė/g=#Omd.|^n/sl׉g DZqemqowݮRzUܜ=ڽ-o/Iۖ;qVʘgPp|mm;6zGl9.8pwWgsJ2qPbe}}UpNjٯ}7TMQKrؽtEx%v w߾8%|j;~|}pK]ơ/ w߾8%|j;~|}pK]ơ/ w&~e_H 8PL7:%ʭ5Kw&U2vwR_+rm'}C7#rWoO&HoG?M$UR7{FU]u ;# !Wk`|W>׹潇9Vn)6)*ҹ{%qV4q>W1vi#T"Qk&GwxcJBJ- Ϸ^ˁxkU}ԣ/3.;]J=<*)cS)ROK9H=,r zX @)cS)Da^ԽQ gxJI=w֣gf*TRj

Corresponding author: Sung, Kyung Mi College of Nursing Institute of Health Sciences, Gyeongsang National University, 816-15 Tel: +82-55-772-8246, Fax: +82-55-772-8222, E-mail: sung@gnu.ac.kr Jinju-daero, Jinju 660-751, Korea.
• Received: December 3, 2014   • Accepted: April 8, 2015

Copyright © 2015 Korean Society of Adult Nursing

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 170 Views
  • 0 Download
  • 3 Crossref
  • 3 Scopus
prev next
  • Purpose
    This studyidentified the reasons why tuberculosis (TB) patients withhold treatment inabid todevelop a assessment scale to select patients who needs nursing intervention in the early stage and decrease the risk of discontinuationof treatment. Sample: There were two samples. A sample of 191 patients with TB and having primary treatment anda secondsample of N who were under re-treatment
  • Methods
    The studydesignincluded qualitativeandquantitativemethods. Qualitativedatawerecollectedfromin-depthinterviewsof TBpatients under re-treatment. The quantitative data were collected from 191 patients with TB under primary treatment.
  • Results
    Exploratory factor analysis revealed 11 factors explaining 69.6% of total variance. These factors were categorized into four subgroups. A depression scale was used to establish concurrent validity. The depression scale had a positive relationship (r=54) with the discontinuing of primary treatment. The internal consistency reliability for the four subgroups was over. 84. The confidence coefficient was Cronbach's .95. The final scale was a self-reported ⍺ four Likert scale including 50 items.
  • Conclusion
    Reliability and validity was established for the scaleand the scale can be used to examine the risk of treatment discontinuation for TB. The scaleis animportant resource for nursing interventions in identifying and treating high risk clients.
Figure 1.
Scale development process for measuring the risk of tuberculosis treatment discontinuation.
kjan-27-156f1.jpg
Table 1.
Item Analysis and Inter-Item Correlation and Reliability for Initial 67 Items (N=191)
Item contents M±SD Corrected item-total correlation Cronbach's ⍺ if item is deleted
1. I have financial difficulties due to job loss after the onset of TB. 3.13±0.97 .20 .97
2. I feel weak in whole body after the onset of TB. 3.08±0.83 .41 .97
3. I am easily tired after the onset of TB. 3.15±0.82 .40 .97
4. I lost much weight after the onset of TB. 3.08±1.03 .22 .97
5. I am socially withdrawn due to TB. 3.12±0.87 .50 .97
6. I am unemployed due to TB despite attempts to be employed. 3.06±0.92 .51 .97
7. People distance me since the onset of TB. 2.78±1.04 .63 .97
8. I lost social position and self esteem after the onset of TB. 2.94±0.93 .61 .97
9. I feel anxious and lonely due to TB. 2.94±0.97 .61 .97
10. I cannot be close to my family due to fear of contamination. 3.12±0.89 .60 .97
11. I worry if my family has been contaminated due to my cough. 3.16±0.88 .45 .97
12. My family distances me since the onset of TB. 2.27±1.15 .60 .97
13. I cannot openly interact with friends since the onset of TB. 2.86±1.02 .61 .97
14. I am very anxious I cannot have a normal social life compared to my friends since the onset of TB. 2.96±0.96 .54 .97
15. My friends avoid me since the onset of TB. 2.55±1.11 .61 .97
16. I don't want to show anyone my lung photos. 2.91±1.03 .44 .97
17. I think TB is an embarrassing disease. 3.04±0.96 .49 .97
18. I am afraid I will be known as a TB patient. 3.08±0.92 .56 .97
19. I don't want to tell people I was hospitalized for TB. 2.98±0.85 .40 .97
20. I take my TB medication in secret. 2.63±1.02 .62 .97
21. My life has become a mess since I became a TB patient. 2.76±0.97 .47 .97
22. I feel shameful because I cannot function as a person since the onset of TB. 2.86±0.94 .64 .97
23. I feel I lost my value since the onset of TB. 2.87±0.99 .66 .97
24. I feel helpless/powerless due to the reality of TB. 2.97±0.91 .61 .97
25. I feel others reject me if/when I wear a mask. 2.82±0.96 .56 .97
26. I feel I have become a weak person since I became a TB care patient. 2.76±0.96 .56 .97
27. I don't want to accept I have a contagious disease. 2.66±1.00 .58 .97
28. I feel less desperate for medication since my symptoms improved. 2.44±1.02 .57 .97
29. My will to take medication is progressively decreasing. 2.21±1.10 .68 .97
30. I thought about stopping treatment after my symptoms improved. 2.15±1.04 .59 .97
31. I often forget the seriousness of TB. 2.24±1.00 .48 .97
32. I have tried alternative medicine because I did not know the importance of medication. 2.02±1.05 .59 .97
33. I feel a rush of stress and pressure when I see large amounts of drugs. 2.90±0.88 .50 .97
34. It is difficult to take medication on time due to irregular meals. 2.65±1.03 .50 .97
35. I don't want to take medication because meals are no longer enjoyable since the onset of TB. 2.81±0.97 .57 .97
36. Sometimes, I don't want to take medication due to repulsion against forced treatment. 2.44±1.08 .54 .97
37. I cannot take medication on time due to the presence of others/other people. 2.18±1.10 .68 .97
38. I fear taking medication due to severe drug side effects. 2.59±0.91 .66 .97
39. My whole body aches when I take medication. 2.56±0.90 .65 .97
40. TB medication is so strong it makes my stomach ache. 2.71±0.97 .53 .97
41. I am distressed by severe nausea and vomiting. 2.70±1.06 .60 .97
42. I get acid reflux and my breath smells bitter. 2.63±0.98 .51 .97
43. I am tired of taking so much medication at once. 2.93±0.93 .46 .97
44. Remembering to take medication on my own is difficult. 2.86±1.00 .46 .97
45. I cannot regularly care for TB treatment. 2.62±1.00 .42 .97
46. I cannot regularly take medication due to my irregular lifestyle. 2.65±1.02 .41 .97
47. I often cannot make hospital visits due to irregular working hours. 2.45±1.09 .46 .97
48. I delayed treatment due to difficulty in selecting a follow up hospital. 2.25±1.03 .54 .97
49. I am reluctant to visit the hospital because there are many tests and long waiting hours. 2.26±1.02 .51 .97
50. It is inconvenient to visit a follow up hospital because it is far. 2.32±0.94 .48 .97
51. Hospital visits are burdensome because I am busy at/with work. 2.29±1.02 .50 .97
52. I have quit medication on my own accord due to powerlessness from TB. 2.48±1.05 .57 .97
53. I forget to take TB medication if/when I drink alcoholic beverages. 2.65±1.05 .51 .97
54. I often forget to take TB medication on a regular basis. 2.39±1.03 .52 .97
55. I don't have enough patience with treatment. 2.63±0.97 .52 .97
56. If I miss a prescription date, I get lazy and not go afterwards. 2.62±1.02 .46 .97
57. I feel there are no visible improvements even if take medication. 2.53±0.86 .58 .97
58. I want to give up treatment, because I have lost trust in medical professionals. 2.01±0.99 .66 .97
59. I get nervous every time I get a test. 2.39±0.88 .53 .97
60. I feel TB medication is not a good treatment for me due to severe side effects. 2.14±0.97 .63 .97
61. I am anxious there seems to be no way to cure TB. 2.43±0.96 .54 .97
62. I feel there is no hope of improvement at my stage. 2.05±1.00 .62 .97
63. I fear I may die due to/ from TB. 2.46±1.06 .54 .97
64. I think TB will reoccur even if I am cured. 2.62±0.93 .44 .97
65. I am depressed only I got a disease. 2.40±0.96 .63 .97
66. I am anxious I will not be able to finish TB treatment due to medication tolerance. 2.49±0.96 .62 .97
67. I am hopeless, because I think I will never be cured. 2.25±0.99 .68 .97

TB=tuberculosis; Range of Inter-item correlation: .01 <r≤ .70.

Table 2.
Factor Analysis of the Scale of the Risk of TB Treatment Discontinuation (N=191)
Item contents Factor loading
1 2 3 4 5 6 7 8 9 10 11
Factor 1: Difficulties of interpersonal relationship
 15. My friends avoid me since the onset of TB. .74 .05 .27 .08 .24 .04 .07 .22 -.01 .08 -.12
 7. People distance me since the onset of TB. .73 .15 .15 .17 .20 .13 .01 .11 .12 .07 -.02
 14. I'm very anxious I cannot have a normal social life compared to my friends. .70 .30 -.05 .13 .03 .03 .14 .07 .05 .16 .04
 13. I cannot openly interact with friends since the onset of TB. .69 .25 .07 .17 .05 .22 .15 .10 -.08 .11 -.01
 9. I feel anxious and lonely due to TB. .66 .31 .13 .17 .05 .19 .03 .13 .17 -.18 .12
 8. I lost social position and self esteem after the onset of TB. .66 .32 .09 .10 .08 .24 -.11 .16 .18 -.11 .15
 12. My family distances me because of TB. .61 .07 .34 .17 .10 .20 .15 .11 -.23 .26 -.25
 6. I am unemployed due to TB despite attempts to be employed. .58 .18 .03 .20 .13 .16 -.08 -.08 .26 -.01 .20
 10. I cannot be close to my family due to fear of contamination. .56 .29 .16 .06 .11 .03 .28 .09 .22 .04 .06
Factor 2: Loss of self-competency as a human being
 24. I feel powerless due to the reality of TB. .20 .75 .22 .15 .01 .01 .11 -.02 .14 .14 .10
 23. I lost my value since the onset of TB. .30 .74 .19 .10 .07 .07 .16 .10 -.02 .11 .13
 22. I feel shameful because I cannot function as a person since the onset of TB. .36 .70 .06 .13 .05 .12 .06 .10 .04 .22 .05
 25. I feel others reject me if I wear a mask. .34 .67 .21 -.01 .03 .02 .09 .13 .07 -.12 .13
 27. I don't want to accept I have a contagious disease. .07 .62 .26 .14 .18 .12 .07 .23 .08 .01 -.18
 20. I take my TB medication in secret. .21 .60 .13 .11 .18 .15 .06 .44 -.05 .08 -.04
 26. I feel I have become a weak person since I became a TB care patient. .18 .59 .03 .20 .07 .29 -.05 .21 .06 .07 .01
 21. My life has become a mess since I became a TB patient. .18 .59 -.13 .18 -.04 .25 -.12 .07 .16 .31 .16
Factor 3: Loss of primary importance for therapeutic compliance
 31. I often forget the seriousness of TB. .01 .02 .75 .06 .10 .24 .10 -.01 .01 .08 .11
 28. I feel less desperate for medication since my symptoms improved. .05 .22 .72 .20 .11 .14 .06 .10 .09 -.05 -.06
 30. I thought about stopping treatment after my symptoms improved. .20 .02 .72 .03 .22 .18 .15 .10 .06 .10 .15
 29. My will to take medication is decreasing. .22 .17 .70 .27 .14 .18 .04 .10 .03 .09 .01
 32. I have tried alternative medicine because I did not know the importance of medication .16 .16 .61 .14 .13 .29 -.04 .14 -.07 .11 .07
 36. Sometimes, I don't want to take medication due to repulsion against forced treatment .06 .22 .59 .15 .30 -.01 .22 -.13 -.12 .12 .08
 58. I want to give up treatment, because I have lost trust in medical professionals. .20 .19 .57 .25 .42 .12 .01 -.02 -.03 .04 .05
Factor 4: Difficulties to overcome side effects from anti-TB medicines
 41. I am distressed by severe nausea and vomiting. .25 .13 .24 .78 .16 .02 .12 -.01 .03 .06 .03
 40. TB medication is so strong it makes my stomach ache. .14 .20 .16 .77 .12 -.01 .02 .02 .03 .11 -.07
 42. I get acid reflux and my breath smells bitter. .21 .03 .12 .76 .10 .06 .01 .05 .09 .13 .14
 43. I am tired of taking so much medication at once. .08 .11 .09 .70 -.05 .13 .26 .02 .01 .13 .20
 39. My whole body aches when I take medication. .14 .32 .24 .64 .18 .10 .07 .24 .09 -.09 -.05
Factor 5: Failure of medication adherence
 54. I often forget to take TB medication on a regular basis. .19 .05 .21 .11 .81 .12 .04 .16 .01 -.05 .12
 55. I don't have enough patience with treatment. .09 .05 .28 .14 .74 .04 .20 .01 -.01 .12 .07
 56. If I miss a prescription date, I get lazy and not go afterwards. .11 .10 .31 .08 .68 .15 .14 -.09 .03 -.01 -.14
 53. I forget to take TB medication when I drink alcoholic beverages. .23 .07 .07 .10 .63 .14 24 .20 -.05 .03 .25
Factor 6: Inconvenience of medical center use
 49. I am reluctant to visit the hospital because there are many tests and long waiting hours. .20 .17 .18 .11 .09 .78 .09 .02 .09 -.08 -.07
 50. It is inconvenient to visit a follow up hospital because it is far. .21 .10 .28 .01 -.03 .70 .04 .11 -.02 .14 .06
 48. I delayed treatment due to difficulty in selecting a follow up hospital. .16 .21 .22 .06 .18 .70 .21 -.01 .06 .07 -.21
 51. Hospital visits are burdensome because I am busy at/with work. .15 .09 .23 -.00 .15 .68 .06 .03 .06 .11 .29
 47. I often cannot make hospital visits due to irregular working hours. .04 .08 .17 .15 .36 .51 .38 -.05 .03 .01 -.06
Factor 7: Having difficulties in maintaining self-care for the TB
 45. I cannot regularly care for TB treatment. .08 .08 .24 .14 .12 .04 .80 .10 -.02 -.06 .09
 46. I cannot regularly take medication due to my irregular lifestyle. .18 .08 .02 .03 .24 .23 .77 .03 .06 .03 -.01
 44. Remembering to take medication on my own is difficult. .04 .05 .05 .46 .19 .17 .59 .07 .07 -.02 .19
Factor 8: A sense of shame as a TB patient
 18. I'm afraid I will be known as a TB patient. .38 .23 .13 .05 .07 .01 .12 .71 .12 .14 .13
 17. I think TB is an embarrassing disease. .38 .20 .10 -.05 .05 .05 .09 .71 .01 .17 .22
 19. I don't want to tell people I was hospitalized for TB. .02 .30 .01 .16 .04 .05 .01 .65 .05 -.08 -.22
Factor 9: Low physical strength to put up with the compliance
 3. I am easily tired after the onset of TB. .12 .04 .02 .12 .04 .12 .01 .09 .85 .17 .07
 2. I feel weak in whole body after the onset of TB. .22 .24 -.02 .05 -.05 .02 .07 .02 .79 .17 -.12
Factor 10: A pessimistic view of the outcome from TB therapy
 64. I think TB will reoccur even if I'm cured. .10 .17 .19 .16 -.01 .05 -.01 .09 .25 .78 -.03
 63. I fear I may die from TB. .11 .28 .18 .20 .12 .14 -.03 .06 .17 .67 .15
Factor 11: Emotional burden to take anti-TB medicines
 33. I feel a rush of stress and pressure when I see large amounts of drugs. .08 .18 .30 .34 .18 -.02 .12 .04 .05 .05 .57
 34. It is difficult to take medication on time due to irregular meals. .10 .26 .20 .23 .26 .05 .30 .02 -.16 .10 .52
 Eigen value 5.41 4.89 4.55 3.82 3.18 3.18 2.46 2.17 1.89 1.73 1.43
 Explained Variance (%) 10.8 9.8 9.1 7.7 6.4 6.4 4.9 4.3 3.8 3.5 2.9
 Accumulative Variance (%) 10.8 20.6 29.7 37.4 43.8 50.2 55.1 59.4 63.2 66.7 69.6

TB=tuberculosis.

Table 3.
Correlation between the Risk of TB Treatment Discontinuation and Depression (N=191)
Variables Risk of TB treatment discontinuation
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 Total
r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p)
Risk of treatment discontinuation F1 1
   
F2 .65 1
  (<.001)  
F3 .47 .45 1
  (<.001) (<.001)  
F4 .44 .44 .50 1
  (<.001) (<.001) (<.001)  
F5 .37 .28 .56 .34 1
  (<.001) (<.001) (<.001) (<.001)  
F6 .41 .38 .53 .29 .48 1
  (<.001) (<.001) (<.001) (<.001) (<.001)  
F7 .35 .29 .41 .44 .47 .39 1
  (<.001) (<.001) (<.001) (<.001) (<.001) (<.001)  
F8 .71 .57 .26 .24 .24 .25 .20 1
  (<.001) (<.001) (<.001) (.001) (.001) (.001) (.005)  
F9 .34 .35 .116 .25 .06 .17 .12 .26 1
  (<.001) (<.001) (.111) (<.001) (.45) (.016) (.093) (<.001)  
F10 .37 .46 .39 .39 .21 .25 .20 .28 .37 1
  (<.001) (<.001) (<.001) (<.001) (.004) (<.001) (.006) (<.001) (<.001)  
F11 .32 .40 .49 .49 .39 .24 .42 .22 .08 .32 1
  (<.001) (<.001) (<.001) (<.001) (<.001) (.001) (<.001) (.002) (.258) (<.001)  
Total .81 .78 .77 .68 .62 .65 .58 .57 .38 .54 .57 1
  (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001)  
Depression .39 .41 .55 .40 .30 .33 .22 .24 .17 .32 .36 .54
(<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (.003) (.001) (.017) (<.001) (<.001) (<.001)

TB=Tuberculosis.

Table 4.
Reliability for the Final 50 Items (N=191
Variables Factor Factor name (number of item) M±SD Cronbach's ⍺ SEM
The stigma of being a TB patient F1 Difficulties of interpersonal relationship 2.84±0.70 .87 .25
F2 Loss of self-competency as a human being 2.79±0.74 .89 .24
F8 A sense of shame to become a TB patient (20 items) 3.03±0.76 .78 .36
Sub-total     2.92±0.65 .93 .16
Loss of patient role for TB treatment F3 Loss of primary importance for therapeutic compliance 2.21±0.79 .88 .28
F10 A pessimistic view of the outcome from TB therapy (9 items) 2.53±0.89 .74 .45
Sub-total     2.49±0.69 .87 .21
An obstacle to complete treatment for the TB F4 Difficulties to overcome side effects from anti-TB medicines 2.71±0.78 .86 .29
F6 Inconvenience of medical center use 2.31±0.80 .84 .32
F9 Low physical strength to put up with the compliance (12 items) 3.12±0.75 .80 .34
Sub-total     2.70±0.67 .84 .19
A lack of will to the therapeutic adherence F5 Failure of medication adherence 2.57±0.84 .84 .34
F7 Having difficulties in maintaining self-care for the TB 2.71±0.84 .78 .40
F11 Emotional burden to take anti-TB medicines (9 items) 2.77±0.84 .70 .46
Sub-total     2.69±0.71 .85 .28
Total   50 items 2.66±0.54 .95 .12

SEM=standard error of measurement; TB=tuberculosis.

  • 1.Lee HMA study for medical facilities utilization patterns of tuberculosis patients and treatment success of tuberculosis in public health centers: by using the nationwide tuberculosis notification data [master's thesis]. Seoul: Hanyang University; 2013.
  • 2.Statistics Korea. Cause of death statistics in 2013. Seoul: Statistics Korea; 2014. [cited 2014 September 28]. Available from:.http://kostat.go.kr/portal/korea/kor_nw/3/index.board?bmode=read&aSeq=330183.
  • 3.Korea Centers for Disease Control and Prevention. A report for current registration statistics of patients with tuberculosis in 2013. Seoul: Korea Centers for Disease Control and Prevention; 2014. [cited 2014 September 28]. Available from:.http://www.cdc.go.kr/CDC/intro/CdcKrIntro0201.jsp?menuIds=HOME001-MNU1154-MNU0005-MNU0011&cid=26973.
  • 4.Cheong CO, Kim SS, Kang MK, Cho EH, Lee EY, Chang CH. Knowledge and attitudes toward tuberculosis among high school students in Busan. Tuberculosis and Respiratory Diseases. 2008;65(5):369-78.
  • 5.Chang KSA relationship of self-efficacy, social support, and therapeutic compliance in patients with tuberculosis [master's thesis]. Jeonnam: Chodang University; 2010.
  • 6.Korea Centers for Disease Control and Prevention. National management guideline for patients with tuberculosis in 2011. Seoul: Korea Centers for Disease Control and Prevention; 2013. [cited 2014 September 28]. Available from:.http://www.cdc.go.kr/CDC/notice/CdcKrTogether0302.jsp?menuIds=HOME001-MNU1154-MNU0004-MNU0088&cid=20376.
  • 7.Guo N, Marra F, Marra CA. Measuring health-related quality oflife in tuberculosis: a systematic review. HealthandQuality of Life Outcome. 2009;7(14):);online.http://dx.doi.org/10.1186/1477-7525-7-14.
  • 8.Kim HS, Ha CK. A study on family support, depression, and quality of life among patients with tuberculosis in a hospital: focusing onmediating effectofdepression. JournalofFamily Relations. 2010;14(4):157-82.
  • 9.Rajeswari R, Muniyandi M, Balasubramanian R, Narayanan PR. Perceptions of tuberculosis patients about their physical, mental and social well-being: a field report from south India. Social Science & Medicine. 2005;60:1845-53. http://dx.doi.org/10.1016/j.socscimed.2004.08.024.
  • 10.Ugarte-Gil C, Ruiz P, Zamudio C, Canaza L, Otero L, Kruger H, et al. Association of major depressive episode with negative outcomes of tuberculosis treatment. 2013;8(7):onlinehttp://dx.doi.org/10.1371/journal.pone.0069514.
  • 11.Atif M, Sulaiman SAS, Shafie AA, Asif M, Sarfraz MK, Low HC, et al. Impact of tuberculosis treatment on health-related quality of life of pulmonary tuberculosis patients: a follow-up study. Health and Quality of Life Outcomes. 2014;12(14):): onlinehttp://dx.doi.org/10.1186/1477-7525-12-19.
  • 12.Dimitrova B, Balabanova D, Atun R, Drobniewski F, Leviche-va V, Coker R. Health service providers' perceptions of barriers to tuberculosis care in Russia. Health Policy and Planning. 2006;21(4):265-74. http://dx.doi.org/10.1093/heapol/czl014.
  • 13.Chang SASubjectivity researchfor tuberculosis treatmentdis-continuation[master'sthesis]. Seoul: Hanyang University; 2000.
  • 14.Kong JH, Lee SS, Kang HY, Park JS. The prevalence of initial drug resistance among pulmonary tuberculosis patients. Tuberculosis and Respiratory Diseases. 2008;64(2):95-101.
  • 15.Park SK, Choi IH, Kim CT, Song SD. Analysis of causes for primary treatment failure of pulmonary tuberculosis. Tuberculosis and Respiratory Diseases. 1997;44(6):1234-44.
  • 16.Elo S, Kyngas H. The qualitative content analysis process. Journal of Advanced Nursing. 2008;62(1):107-15. http://dx.doi.org/10.1111/j.1365-2648.2007.04569.x̆.
  • 17.Waltz CW, Bausell RBNursing research: design, statistics and computer analysis. Philadelphia: F.A. Davis; 1981.
  • 18.Lee EO, Gu MO, Kwo IG, Kim KS, Kim IJ, Kim JI, et alResearch evaluation and utilization. Seoul: Koonja; 2007.
  • 19.Tabachnick BG, Fidell LSUsing multivariate statistics. New York: Harper and Row; 1989.
  • 20.Beck ATDepression: clinical, experimental and theoretical aspects. New York: Harper & Row; 1967.
  • 21.Lee YH, Song CY. A study of the reliability and the validity of the BDI, SDS, and MMPI-D scales. The Korean Journal of Clinical Psychology. 1991;10(1):98-113.
  • 22.Han SS, Lee SCSPSS nursing and health statistical analysis. Seoul: Hyunmoonsa; 2006.
  • 23.An SH, Park DS, Lee SM. The clinical application of ICF for functional ability analysis of stroke patients. The Journal of Korean Society of Occupational. 2009;17(4):37-44.
  • 24.Baral SC, Kariki DK, Newel JN. Cause of stigma and discrimination associated with tuberculosis in Nepal: A qualitative study. Public Health. 2007;16(7):onlinehttp://dx.doi.org/10.1186/1471-2458-7-211.
  • 25.Sung YS, Lee YH. Relationship of illness perception, self-efficacy, and self-care among pulmonary tuberculosis patients. The Journal of Korean Academic Society of Adult Nursing. 2011;23(1):31-9.
  • 26.Kang KJ, Tae YS, Lee BS, Son SK, Yang HJ, Mok KH. A study on compliance in self-medication of pulmonary tuberculosis patients. The Journal of Korean Academic Society of Adult Nursing. 1998;10(3):446-59.
  • 27.Suh SM. A study on support by families of patients with pulmonary tuberculosis and compliance with sick role behavior. Journal of Korean Academy of Nursing. 1993;23(4):555-68.

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Identifying Predictors of Unfavorable Treatment Outcomes in Tuberculosis Patients
      Ji Yeon Lee, Jun-Pyo Myong, Younghyun Kim, Ina Jeong, Joohae Kim, Sooim Sin, Yunhyung Kwon, Chieeun Song, Joon-Sung Joh
      International Journal of Environmental Research and Public Health.2024; 21(11): 1454.     CrossRef
    • Factors Influencing the Medication Adherence in Patients with Pulmonary Tuberculosis in the COVID-19 Pandemic
      Bongsil Lim, Min Young Kim
      The Korean Journal of Rehabilitation Nursing.2023; 26(2): 87.     CrossRef
    • Self-care Efficacy and Health-related Quality of Life among Patients on Primary Treatment for Pulmonary Tuberculosis: The Mediating Effects of Self-Care Performance
      Hyun Ju Lee, Jiyoung Park
      Korean Journal of Adult Nursing.2020; 32(3): 305.     CrossRef

    Download Citation

    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:

    Include:

    The Development of a Scale Assessing the Risk of Discontinuation of Tuberculosis Treatment
    Korean J Adult Nurs. 2015;27(2):156-169.   Published online April 30, 2015
    Download Citation
    Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

    Format:
    • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
    • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
    Include:
    • Citation for the content below
    The Development of a Scale Assessing the Risk of Discontinuation of Tuberculosis Treatment
    Korean J Adult Nurs. 2015;27(2):156-169.   Published online April 30, 2015
    Close

    Figure

    • 0
    The Development of a Scale Assessing the Risk of Discontinuation of Tuberculosis Treatment
    Image
    Figure 1. Scale development process for measuring the risk of tuberculosis treatment discontinuation.
    The Development of a Scale Assessing the Risk of Discontinuation of Tuberculosis Treatment

    Item Analysis and Inter-Item Correlation and Reliability for Initial 67 Items (N=191)

    Item contents M±SD Corrected item-total correlation Cronbach's ⍺ if item is deleted
    1. I have financial difficulties due to job loss after the onset of TB. 3.13±0.97 .20 .97
    2. I feel weak in whole body after the onset of TB. 3.08±0.83 .41 .97
    3. I am easily tired after the onset of TB. 3.15±0.82 .40 .97
    4. I lost much weight after the onset of TB. 3.08±1.03 .22 .97
    5. I am socially withdrawn due to TB. 3.12±0.87 .50 .97
    6. I am unemployed due to TB despite attempts to be employed. 3.06±0.92 .51 .97
    7. People distance me since the onset of TB. 2.78±1.04 .63 .97
    8. I lost social position and self esteem after the onset of TB. 2.94±0.93 .61 .97
    9. I feel anxious and lonely due to TB. 2.94±0.97 .61 .97
    10. I cannot be close to my family due to fear of contamination. 3.12±0.89 .60 .97
    11. I worry if my family has been contaminated due to my cough. 3.16±0.88 .45 .97
    12. My family distances me since the onset of TB. 2.27±1.15 .60 .97
    13. I cannot openly interact with friends since the onset of TB. 2.86±1.02 .61 .97
    14. I am very anxious I cannot have a normal social life compared to my friends since the onset of TB. 2.96±0.96 .54 .97
    15. My friends avoid me since the onset of TB. 2.55±1.11 .61 .97
    16. I don't want to show anyone my lung photos. 2.91±1.03 .44 .97
    17. I think TB is an embarrassing disease. 3.04±0.96 .49 .97
    18. I am afraid I will be known as a TB patient. 3.08±0.92 .56 .97
    19. I don't want to tell people I was hospitalized for TB. 2.98±0.85 .40 .97
    20. I take my TB medication in secret. 2.63±1.02 .62 .97
    21. My life has become a mess since I became a TB patient. 2.76±0.97 .47 .97
    22. I feel shameful because I cannot function as a person since the onset of TB. 2.86±0.94 .64 .97
    23. I feel I lost my value since the onset of TB. 2.87±0.99 .66 .97
    24. I feel helpless/powerless due to the reality of TB. 2.97±0.91 .61 .97
    25. I feel others reject me if/when I wear a mask. 2.82±0.96 .56 .97
    26. I feel I have become a weak person since I became a TB care patient. 2.76±0.96 .56 .97
    27. I don't want to accept I have a contagious disease. 2.66±1.00 .58 .97
    28. I feel less desperate for medication since my symptoms improved. 2.44±1.02 .57 .97
    29. My will to take medication is progressively decreasing. 2.21±1.10 .68 .97
    30. I thought about stopping treatment after my symptoms improved. 2.15±1.04 .59 .97
    31. I often forget the seriousness of TB. 2.24±1.00 .48 .97
    32. I have tried alternative medicine because I did not know the importance of medication. 2.02±1.05 .59 .97
    33. I feel a rush of stress and pressure when I see large amounts of drugs. 2.90±0.88 .50 .97
    34. It is difficult to take medication on time due to irregular meals. 2.65±1.03 .50 .97
    35. I don't want to take medication because meals are no longer enjoyable since the onset of TB. 2.81±0.97 .57 .97
    36. Sometimes, I don't want to take medication due to repulsion against forced treatment. 2.44±1.08 .54 .97
    37. I cannot take medication on time due to the presence of others/other people. 2.18±1.10 .68 .97
    38. I fear taking medication due to severe drug side effects. 2.59±0.91 .66 .97
    39. My whole body aches when I take medication. 2.56±0.90 .65 .97
    40. TB medication is so strong it makes my stomach ache. 2.71±0.97 .53 .97
    41. I am distressed by severe nausea and vomiting. 2.70±1.06 .60 .97
    42. I get acid reflux and my breath smells bitter. 2.63±0.98 .51 .97
    43. I am tired of taking so much medication at once. 2.93±0.93 .46 .97
    44. Remembering to take medication on my own is difficult. 2.86±1.00 .46 .97
    45. I cannot regularly care for TB treatment. 2.62±1.00 .42 .97
    46. I cannot regularly take medication due to my irregular lifestyle. 2.65±1.02 .41 .97
    47. I often cannot make hospital visits due to irregular working hours. 2.45±1.09 .46 .97
    48. I delayed treatment due to difficulty in selecting a follow up hospital. 2.25±1.03 .54 .97
    49. I am reluctant to visit the hospital because there are many tests and long waiting hours. 2.26±1.02 .51 .97
    50. It is inconvenient to visit a follow up hospital because it is far. 2.32±0.94 .48 .97
    51. Hospital visits are burdensome because I am busy at/with work. 2.29±1.02 .50 .97
    52. I have quit medication on my own accord due to powerlessness from TB. 2.48±1.05 .57 .97
    53. I forget to take TB medication if/when I drink alcoholic beverages. 2.65±1.05 .51 .97
    54. I often forget to take TB medication on a regular basis. 2.39±1.03 .52 .97
    55. I don't have enough patience with treatment. 2.63±0.97 .52 .97
    56. If I miss a prescription date, I get lazy and not go afterwards. 2.62±1.02 .46 .97
    57. I feel there are no visible improvements even if take medication. 2.53±0.86 .58 .97
    58. I want to give up treatment, because I have lost trust in medical professionals. 2.01±0.99 .66 .97
    59. I get nervous every time I get a test. 2.39±0.88 .53 .97
    60. I feel TB medication is not a good treatment for me due to severe side effects. 2.14±0.97 .63 .97
    61. I am anxious there seems to be no way to cure TB. 2.43±0.96 .54 .97
    62. I feel there is no hope of improvement at my stage. 2.05±1.00 .62 .97
    63. I fear I may die due to/ from TB. 2.46±1.06 .54 .97
    64. I think TB will reoccur even if I am cured. 2.62±0.93 .44 .97
    65. I am depressed only I got a disease. 2.40±0.96 .63 .97
    66. I am anxious I will not be able to finish TB treatment due to medication tolerance. 2.49±0.96 .62 .97
    67. I am hopeless, because I think I will never be cured. 2.25±0.99 .68 .97

    TB=tuberculosis; Range of Inter-item correlation: .01 <r≤ .70.

    Factor Analysis of the Scale of the Risk of TB Treatment Discontinuation (N=191)

    Item contents Factor loading
    1 2 3 4 5 6 7 8 9 10 11
    Factor 1: Difficulties of interpersonal relationship
     15. My friends avoid me since the onset of TB. .74 .05 .27 .08 .24 .04 .07 .22 -.01 .08 -.12
     7. People distance me since the onset of TB. .73 .15 .15 .17 .20 .13 .01 .11 .12 .07 -.02
     14. I'm very anxious I cannot have a normal social life compared to my friends. .70 .30 -.05 .13 .03 .03 .14 .07 .05 .16 .04
     13. I cannot openly interact with friends since the onset of TB. .69 .25 .07 .17 .05 .22 .15 .10 -.08 .11 -.01
     9. I feel anxious and lonely due to TB. .66 .31 .13 .17 .05 .19 .03 .13 .17 -.18 .12
     8. I lost social position and self esteem after the onset of TB. .66 .32 .09 .10 .08 .24 -.11 .16 .18 -.11 .15
     12. My family distances me because of TB. .61 .07 .34 .17 .10 .20 .15 .11 -.23 .26 -.25
     6. I am unemployed due to TB despite attempts to be employed. .58 .18 .03 .20 .13 .16 -.08 -.08 .26 -.01 .20
     10. I cannot be close to my family due to fear of contamination. .56 .29 .16 .06 .11 .03 .28 .09 .22 .04 .06
    Factor 2: Loss of self-competency as a human being
     24. I feel powerless due to the reality of TB. .20 .75 .22 .15 .01 .01 .11 -.02 .14 .14 .10
     23. I lost my value since the onset of TB. .30 .74 .19 .10 .07 .07 .16 .10 -.02 .11 .13
     22. I feel shameful because I cannot function as a person since the onset of TB. .36 .70 .06 .13 .05 .12 .06 .10 .04 .22 .05
     25. I feel others reject me if I wear a mask. .34 .67 .21 -.01 .03 .02 .09 .13 .07 -.12 .13
     27. I don't want to accept I have a contagious disease. .07 .62 .26 .14 .18 .12 .07 .23 .08 .01 -.18
     20. I take my TB medication in secret. .21 .60 .13 .11 .18 .15 .06 .44 -.05 .08 -.04
     26. I feel I have become a weak person since I became a TB care patient. .18 .59 .03 .20 .07 .29 -.05 .21 .06 .07 .01
     21. My life has become a mess since I became a TB patient. .18 .59 -.13 .18 -.04 .25 -.12 .07 .16 .31 .16
    Factor 3: Loss of primary importance for therapeutic compliance
     31. I often forget the seriousness of TB. .01 .02 .75 .06 .10 .24 .10 -.01 .01 .08 .11
     28. I feel less desperate for medication since my symptoms improved. .05 .22 .72 .20 .11 .14 .06 .10 .09 -.05 -.06
     30. I thought about stopping treatment after my symptoms improved. .20 .02 .72 .03 .22 .18 .15 .10 .06 .10 .15
     29. My will to take medication is decreasing. .22 .17 .70 .27 .14 .18 .04 .10 .03 .09 .01
     32. I have tried alternative medicine because I did not know the importance of medication .16 .16 .61 .14 .13 .29 -.04 .14 -.07 .11 .07
     36. Sometimes, I don't want to take medication due to repulsion against forced treatment .06 .22 .59 .15 .30 -.01 .22 -.13 -.12 .12 .08
     58. I want to give up treatment, because I have lost trust in medical professionals. .20 .19 .57 .25 .42 .12 .01 -.02 -.03 .04 .05
    Factor 4: Difficulties to overcome side effects from anti-TB medicines
     41. I am distressed by severe nausea and vomiting. .25 .13 .24 .78 .16 .02 .12 -.01 .03 .06 .03
     40. TB medication is so strong it makes my stomach ache. .14 .20 .16 .77 .12 -.01 .02 .02 .03 .11 -.07
     42. I get acid reflux and my breath smells bitter. .21 .03 .12 .76 .10 .06 .01 .05 .09 .13 .14
     43. I am tired of taking so much medication at once. .08 .11 .09 .70 -.05 .13 .26 .02 .01 .13 .20
     39. My whole body aches when I take medication. .14 .32 .24 .64 .18 .10 .07 .24 .09 -.09 -.05
    Factor 5: Failure of medication adherence
     54. I often forget to take TB medication on a regular basis. .19 .05 .21 .11 .81 .12 .04 .16 .01 -.05 .12
     55. I don't have enough patience with treatment. .09 .05 .28 .14 .74 .04 .20 .01 -.01 .12 .07
     56. If I miss a prescription date, I get lazy and not go afterwards. .11 .10 .31 .08 .68 .15 .14 -.09 .03 -.01 -.14
     53. I forget to take TB medication when I drink alcoholic beverages. .23 .07 .07 .10 .63 .14 24 .20 -.05 .03 .25
    Factor 6: Inconvenience of medical center use
     49. I am reluctant to visit the hospital because there are many tests and long waiting hours. .20 .17 .18 .11 .09 .78 .09 .02 .09 -.08 -.07
     50. It is inconvenient to visit a follow up hospital because it is far. .21 .10 .28 .01 -.03 .70 .04 .11 -.02 .14 .06
     48. I delayed treatment due to difficulty in selecting a follow up hospital. .16 .21 .22 .06 .18 .70 .21 -.01 .06 .07 -.21
     51. Hospital visits are burdensome because I am busy at/with work. .15 .09 .23 -.00 .15 .68 .06 .03 .06 .11 .29
     47. I often cannot make hospital visits due to irregular working hours. .04 .08 .17 .15 .36 .51 .38 -.05 .03 .01 -.06
    Factor 7: Having difficulties in maintaining self-care for the TB
     45. I cannot regularly care for TB treatment. .08 .08 .24 .14 .12 .04 .80 .10 -.02 -.06 .09
     46. I cannot regularly take medication due to my irregular lifestyle. .18 .08 .02 .03 .24 .23 .77 .03 .06 .03 -.01
     44. Remembering to take medication on my own is difficult. .04 .05 .05 .46 .19 .17 .59 .07 .07 -.02 .19
    Factor 8: A sense of shame as a TB patient
     18. I'm afraid I will be known as a TB patient. .38 .23 .13 .05 .07 .01 .12 .71 .12 .14 .13
     17. I think TB is an embarrassing disease. .38 .20 .10 -.05 .05 .05 .09 .71 .01 .17 .22
     19. I don't want to tell people I was hospitalized for TB. .02 .30 .01 .16 .04 .05 .01 .65 .05 -.08 -.22
    Factor 9: Low physical strength to put up with the compliance
     3. I am easily tired after the onset of TB. .12 .04 .02 .12 .04 .12 .01 .09 .85 .17 .07
     2. I feel weak in whole body after the onset of TB. .22 .24 -.02 .05 -.05 .02 .07 .02 .79 .17 -.12
    Factor 10: A pessimistic view of the outcome from TB therapy
     64. I think TB will reoccur even if I'm cured. .10 .17 .19 .16 -.01 .05 -.01 .09 .25 .78 -.03
     63. I fear I may die from TB. .11 .28 .18 .20 .12 .14 -.03 .06 .17 .67 .15
    Factor 11: Emotional burden to take anti-TB medicines
     33. I feel a rush of stress and pressure when I see large amounts of drugs. .08 .18 .30 .34 .18 -.02 .12 .04 .05 .05 .57
     34. It is difficult to take medication on time due to irregular meals. .10 .26 .20 .23 .26 .05 .30 .02 -.16 .10 .52
     Eigen value 5.41 4.89 4.55 3.82 3.18 3.18 2.46 2.17 1.89 1.73 1.43
     Explained Variance (%) 10.8 9.8 9.1 7.7 6.4 6.4 4.9 4.3 3.8 3.5 2.9
     Accumulative Variance (%) 10.8 20.6 29.7 37.4 43.8 50.2 55.1 59.4 63.2 66.7 69.6

    TB=tuberculosis.

    Correlation between the Risk of TB Treatment Discontinuation and Depression (N=191)

    Variables Risk of TB treatment discontinuation
    F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 Total
    r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p) r (p)
    Risk of treatment discontinuation F1 1
       
    F2 .65 1
      (<.001)  
    F3 .47 .45 1
      (<.001) (<.001)  
    F4 .44 .44 .50 1
      (<.001) (<.001) (<.001)  
    F5 .37 .28 .56 .34 1
      (<.001) (<.001) (<.001) (<.001)  
    F6 .41 .38 .53 .29 .48 1
      (<.001) (<.001) (<.001) (<.001) (<.001)  
    F7 .35 .29 .41 .44 .47 .39 1
      (<.001) (<.001) (<.001) (<.001) (<.001) (<.001)  
    F8 .71 .57 .26 .24 .24 .25 .20 1
      (<.001) (<.001) (<.001) (.001) (.001) (.001) (.005)  
    F9 .34 .35 .116 .25 .06 .17 .12 .26 1
      (<.001) (<.001) (.111) (<.001) (.45) (.016) (.093) (<.001)  
    F10 .37 .46 .39 .39 .21 .25 .20 .28 .37 1
      (<.001) (<.001) (<.001) (<.001) (.004) (<.001) (.006) (<.001) (<.001)  
    F11 .32 .40 .49 .49 .39 .24 .42 .22 .08 .32 1
      (<.001) (<.001) (<.001) (<.001) (<.001) (.001) (<.001) (.002) (.258) (<.001)  
    Total .81 .78 .77 .68 .62 .65 .58 .57 .38 .54 .57 1
      (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (<.001)  
    Depression .39 .41 .55 .40 .30 .33 .22 .24 .17 .32 .36 .54
    (<.001) (<.001) (<.001) (<.001) (<.001) (<.001) (.003) (.001) (.017) (<.001) (<.001) (<.001)

    TB=Tuberculosis.

    Reliability for the Final 50 Items (N=191

    Variables Factor Factor name (number of item) M±SD Cronbach's ⍺ SEM
    The stigma of being a TB patient F1 Difficulties of interpersonal relationship 2.84±0.70 .87 .25
    F2 Loss of self-competency as a human being 2.79±0.74 .89 .24
    F8 A sense of shame to become a TB patient (20 items) 3.03±0.76 .78 .36
    Sub-total     2.92±0.65 .93 .16
    Loss of patient role for TB treatment F3 Loss of primary importance for therapeutic compliance 2.21±0.79 .88 .28
    F10 A pessimistic view of the outcome from TB therapy (9 items) 2.53±0.89 .74 .45
    Sub-total     2.49±0.69 .87 .21
    An obstacle to complete treatment for the TB F4 Difficulties to overcome side effects from anti-TB medicines 2.71±0.78 .86 .29
    F6 Inconvenience of medical center use 2.31±0.80 .84 .32
    F9 Low physical strength to put up with the compliance (12 items) 3.12±0.75 .80 .34
    Sub-total     2.70±0.67 .84 .19
    A lack of will to the therapeutic adherence F5 Failure of medication adherence 2.57±0.84 .84 .34
    F7 Having difficulties in maintaining self-care for the TB 2.71±0.84 .78 .40
    F11 Emotional burden to take anti-TB medicines (9 items) 2.77±0.84 .70 .46
    Sub-total     2.69±0.71 .85 .28
    Total   50 items 2.66±0.54 .95 .12

    SEM=standard error of measurement; TB=tuberculosis.

    Table 1. Item Analysis and Inter-Item Correlation and Reliability for Initial 67 Items (N=191)

    TB=tuberculosis; Range of Inter-item correlation: .01 <r≤ .70.

    Table 2. Factor Analysis of the Scale of the Risk of TB Treatment Discontinuation (N=191)

    TB=tuberculosis.

    Table 3. Correlation between the Risk of TB Treatment Discontinuation and Depression (N=191)

    TB=Tuberculosis.

    Table 4. Reliability for the Final 50 Items (N=191

    SEM=standard error of measurement; TB=tuberculosis.

    TOP